



Medical Coverage Policy

Effective Date.....10/15/2021
Next Review Date..... 6/15/2022
Coverage Policy Number 0089

Infertility Services

Table of Contents

Overview	1
Coverage Policy.....	1
General Background.....	5
Medicare Coverage Determinations	22
Coding/Billing Information.....	22
References	32

Related Coverage Resources

- [Acupuncture](#)
- [Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis](#)
- [Hyperbaric Oxygen Therapy, Systemic & Topical Infertility Injectables](#)
- [Recurrent Pregnancy Loss: Diagnosis and Treatment](#)
- [Testosterone Therapy](#)

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment and have discretion in making individual coverage determinations. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Overview

This Coverage Policy addresses diagnostic testing to establish the etiology of infertility and infertility treatments.

Coverage Policy

Coverage of infertility diagnostic and treatment services varies across plans. Testing to determine fertility is only available under an applicable infertility benefit plan. In addition, fertility preservation services are only available under an applicable fertility preservation and/or conception benefit, unless state mandates apply. Refer to the customer's benefit plan document for coverage details.

In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

State mandates may require coverage for some infertility-related services, including certain fertility preservation services. State mandates generally define fertility preservation services as procedures consistent with established medical practices and professional guidelines published by the American Society for Reproductive Medicine, the American Society of Clinical Oncology, or other reputable

professional medical organizations. According to the American Society of Reproductive Medicine (ASRM) and American Society for Clinical Oncology (ASCO) medical practices and guidelines, fertility preservation procedures are defined as those procedures indicated for an individual facing infertility due to chemotherapy, pelvic radiotherapy, or other surgical procedures expected to render one permanently infertile (e.g., hysterectomy, oophorectomy). Please refer to the applicable state mandate for further detail.

When not clearly specified in the benefit plan, infertility is defined as ONE of the following:

- The inability of opposite-sex partners to achieve conception after at least one year of unprotected intercourse.
- The inability of opposite-sex partners to achieve conception after six months of unprotected intercourse when the female partner trying to conceive is age 35 or older.
- The inability of a woman, with or without an opposite-sex partner, to achieve conception after at least six trials of medically supervised artificial insemination over a one-year period.
- The inability of a woman, with or without an opposite-sex partner, after at least three trials of medically supervised artificial insemination over a six-month period of time when the female partner trying to conceive is age 35 or older.

In the absence of a diagnosis of infertility, in-vitro fertilization (IVF) services are considered not medically necessary.

Once an individual meets the definition of infertility as outlined in the benefit plan or as listed above, the following services associated with establishing the etiology of infertility are generally covered under the medical benefits of the infertility plan option when available.

DIAGNOSTIC TESTING TO ESTABLISH THE ETIOLOGY OF INFERTILITY

The following services are considered medically necessary, when performed solely to establish the underlying etiology of infertility:

Evaluation of the female factor:

- history and physical examination
- laboratory tests: thyroid stimulating hormone (TSH), prolactin, follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, progesterone
- ultrasound of the pelvis to assess pelvic organs/structures
- hysteroscopy
- hysterosalpingography
- sonohysterography
- diagnostic laparoscopy with or without chromotubation
- ovarian reserve testing using anti-mullerian hormone (AMH) level, cycle day 3 FSH, ultrasonography for antral follicle assessment, or clomiphene challenge test when ANY of the following criteria is met:
 - women over age 35
 - family history of early menopause
 - single ovary or history or previous ovarian surgery, chemotherapy, or pelvic radiation therapy
 - unexplained infertility
 - previous poor response to gonadotropin stimulation
 - planning treatment with assisted reproductive technologies (e.g., IVF)

Evaluation of the male factor:

- history and physical examination
- semen analysis: two specimens at least one month apart, to evaluate semen volume, concentration, motility, pH, fructose, leukocyte count, microbiology, and morphology.

- additional laboratory tests: endocrine evaluation (including FSH, total and free testosterone, prolactin, LH, TSH), antisperm antibodies, post-ejaculatory urinalysis
- transrectal ultrasound (TRUS), scrotal ultrasound
- vasography and testicular biopsy in individuals with azoospermia
- scrotal exploration
- testicular biopsy

TREATMENT OF INFERTILITY

If benefit coverage for infertility treatment is available, the following treatment services may be considered medically necessary:

Female infertility treatment services:

- U.S. Food and Drug Administration (FDA)-approved ovulation induction medications
- ovulation monitoring studies such as ultrasound and endocrine evaluation
- tubal recanalization, fluoroscopic/hysteroscopic selective tube cannulation, tuboplasty, salpingostomy, fimbrioplasty, tubal anastomosis, and salpingectomy (**NOTE:** Procedures performed to reverse female voluntary sterilization are not covered, even if benefits are available for infertility treatment.)
- surgical laparoscopy, therapeutic hysteroscopy, cervical recanalization, lysis of adhesions, myomectomy, removal of tumors and cysts, septate uterus repair, ovarian wedge resection, ovarian drilling
- in vitro fertilization with embryo transfer (IVF-ET), in vitro with elective single embryo transfer (eSET), tubal embryo transfer (TET), low tubal ovum transfer (LTOT), pronuclear stage transfer (PROST), or natural cycle IVF, and associated services, including the following: ovulation induction, oocyte retrieval, sperm preparation and washing, associated laboratory tests and ultrasounds, mock embryo transfer/uterine sounding, embryo assessment and transfer, and embryologist services
- assisted embryo hatching for women with **ANY** of the following criteria:
 - individuals 38 years of age or older
 - elevated day-3 FSH
 - increased zona thickness on microscopy
 - three or more IVF-attempt failures related to failed implantation
- intracytoplasmic sperm injection (ICSI) and associated services, including sperm extraction and retrieval procedures

Male infertility treatment services:

- pharmacologic treatment of endocrinopathies including hypogonadotropic hypogonadism with FDA-approved drugs such as human chorionic gonadotropins, human menopausal gonadotropin or pulsatile gonadotropin-releasing hormone, corticosteroids, and androgens
- surgical/microsurgical reconstruction or repair of the vas and/or epididymis or other epididymis surgery, such as vasovasostomy, epididymovasostomy, and epididymectomy (**NOTE:** Procedures performed to reverse voluntary male sterilization are not covered, even if benefits are available for infertility treatment.)
- transurethral resection of the ejaculatory ducts (TURED) for the treatment of ejaculatory duct obstruction
- repair of varicocele, excision of tumors (e.g., epididymal), testicular biopsy, orchiopexy, spermatic vein ligation, and excision of spermatocele
- seminal tract washout
- sperm extraction and retrieval procedures such as: electroejaculation, microsurgical epididymal sperm aspiration (MESA), testicular sperm aspiration (TESA), testicular fine needle aspiration (TEFNA), testicular sperm extraction (TESE), microscopic-TESE, percutaneous epididymal sperm aspiration (PESA), vasal sperm aspiration, and seminal vesicle sperm aspiration

CRYOPRESERVATION SERVICES

Coverage of cryopreservation services varies across plans and may be governed by state mandates.

If benefit coverage for cryopreservation and/or related services are available and there is no state mandate requiring coverage of more extensive fertility preservation services, the following apply:

Cryopreservation, storage and thawing of EITHER of the following is considered medically necessary:

- embryos, only while the individual is currently under covered active infertility treatment
- mature oocyte(s), only while the individual is currently under covered active infertility treatment and when **BOTH** of the following criteria are met:
 - a covered IVF cycle using fresh oocyte(s) for fertilization
 - an inability to obtain viable sperm for oocyte fertilization at the time of oocyte retrieval

Each of the following is considered experimental, investigational or unproven:

- Cryopreservation of immature oocytes, including in vitro maturation
- Retrieval, cryopreservation, storage, thawing, and re-transplantation of testicular reproductive tissue
- Retrieval, cryopreservation, storage, thawing, and re-transplantation of ovarian reproductive tissue (Unless applicable state mandate requires coverage for fertility preservation.)

Many benefit plans exclude cryopreservation, storage, and thawing of the following, even when benefits are available for infertility treatment. In addition, these services are considered not medically necessary:

- embryos when not undergoing covered active infertility treatment
- sperm
- oocytes for any indication other than listed above

Experimental/Investigational/Unproven

Each of the following infertility services or tests are considered experimental, investigational, or unproven:

- acupuncture
- hyperbaric oxygen therapy for IVF and/ or treatment of male factor infertility
- intravaginal culture of oocytes (e.g., INVOCell)
- immunological testing (e.g., antiprothrombin antibodies, embryotoxicity assay, circulating natural killer cell measurement, antiphospholipid antibodies, reproductive immunophenotype [RIP], T1 and T2 Helper ratios)
- immune treatments (e.g., peri-implantation glucocorticoids, anti-tumor necrosis factor agents, leukocyte immunization, IV immunoglobulins)
- co-culturing of embryos/oocytes (i.e., culture of oocyte(s), embryo(s), less than 4 days with co-culture)
- computer-assisted sperm motion analysis
- direct intraperitoneal insemination, intrafollicular insemination, fallopian tube sperm transfusion
- endometrial receptivity testing (e.g., Endometrial Function Test™ [EFT®], integrin testing, Beta-3 integrin test, E-tegrity®, endometrial receptivity array [ERA])
- fine needle aspiration mapping
- hemizona test
- hyaluronan binding assay (HBA)
- serum inhibin B
- sperm viability test (e.g., hypo-osmotic swelling test), when performed as a diagnostic test
- the use of sperm precursors (i.e., round or elongated spermatid nuclei, immature sperm) in the treatment of infertility
- sperm-capacitation assessment (e.g., Cap-Score™ Assay [Androvia LifeSciences, Mountainside, New Jersey])
- manual soft tissue therapy for the treatment of pelvic adhesions (WURN Technique®, Clear Passage Therapy)
- laser-assisted necrotic blastomere removal from cryopreserved embryos
- reactive oxygen species testing (ROS)
- time-lapse monitoring/imaging of embryos (e.g., EmbryoScope, Eeva™ Test)

- vaginal microbiome testing (e.g., SmartJane™ screening test [Biome, Inc])
- uterine transplantation
- saline-air infused sono- hysterosalpingogram (e.g., femVue® [Femasys, Inc.])

Many benefit plans exclude the following services even when benefits are available for infertility treatment. In addition, all of these services are considered not medically necessary:

- services associated with the reversal of voluntary sterilization
- infertility services when the infertility is caused by or related to voluntary sterilization
- donor charges, fees and services, including services associated with donor sperm and donor oocytes
- infertility services rendered to a surrogate and surrogate fees
- commercially available over-the-counter home ovulation prediction test kits or pregnancy test kits

General Background

Infertility is defined as the failure to achieve pregnancy after 12 months or more of regular unprotected intercourse or due to an impairment of one's capacity to reproduce either as an individual or with her/his partner (American Society of Reproductive Medicine [ASRM], 2020; American College of Obstetricians and Gynecologists [ACOG], 2019). Earlier evaluation and treatment may be warranted based on medical history and physical findings and is reasonable after six months for women over the age of 35 years (ASRM, 2019; ACOG, 2019, American urological Association/ASRM, 2020). In addition, the inability of a woman to achieve conception after six trials of medically supervised artificial insemination over a one-year period may necessitate evaluation for infertility.

Infertility can affect one or both reproductive partners. Some underlying factors are reversible through medical intervention; the major underlying causes of infertility include: ovulatory, tubal, cervical, uterine/endometrial, and male partner factors.

Disparities in infertility and access to infertility treatments, such as assisted reproductive technology (ART), by race/ethnicity, have been reported. The ASRM Ethics Committee Opinion (2021) indicates that many factors, such as economic, racial, ethnic, geographic, and other disparities affect both access to fertility treatments and treatment outcomes. More specifically, both social and cultural factors, including individual or systemic discrimination that disadvantages certain people because of their race, ethnicity, sexual orientation, or gender identity contribute to disparities. Within this report the authors note a publication by Armstrong and Plowdan (2012) a group of authors using the Society for Assisted Reproductive Technologies Clinical Outcome Reporting System (SARTCORS) data to compare outcomes between cycles from black-non-Hispanic women and white non-Hispanic women found race to be a strong independent predictor of live birth outcomes in ART cycles. Moreover, when African-American, Asian, and Hispanic women attain access to ART, they experience lower success rates compared with non-Hispanic white women. The findings include evidence of lower implantation and clinical-pregnancy rates as well as increased miscarriage rates among certain minority women. The ASRM concluded disparity in infertility and access to treatment along with differences in treatment success are concerning, the results are not well understood, and they require additional evaluation (ASRM, 2021).

Diagnostic Testing To Establish the Etiology of Infertility

Formal evaluation of infertility is generally initiated in women attempting pregnancy who fail to conceive after one year or more of regular, unprotected intercourse. However, there are an increasing number of women over the age of 35 who are seeking infertility services. Since reproductive potential decreases in the early to mid-thirties, for this age group formal evaluation typically begins earlier. For couples over age 35 it is generally recommended that infertility testing begins after 6 months of unsuccessful attempts at conception (ASRM, 2019; ACOG, 2014; Williams, Elam, 2007; Institute for Clinical Systems Improvement [ICSI], 2004). In some cases, an evaluation may be warranted prior to one year if there is a known male infertility risk factor such as bilateral cryptorchidism or known female risk factor (AUA, 2011a).

The preliminary approach to infertility typically begins with the evaluation of ovulatory, tubal, and male factors, and involves physical examination, laboratory studies and diagnostic testing. Other potential contributing causes that may be explored include genetic factors and immunological factors.

The female infertility diagnostic workup to determine the underlying etiology includes basic evaluation of ovulatory dysfunction including basal body temperature recordings, laboratory studies and hormone levels. Additional studies are performed when the initial workup fails to provide definitive information. Tests may include:

- ultrasound
- hysteroscopy
- hysterosalpingography
- diagnostic laparoscopy with or without chromotubation
- sonohysterography
- ovarian reserve testing

Conventional hysterosalpingogram (HSG) is an x-ray procedure where contrast medium is injected thru the cervix into the uterine cavity to assess the inner size and shape of the uterus and patency of the fallopian tubes. Sonohysterography is an ultrasound procedure performed to visualize the inside of the uterine cavity and involves the installation of fluid into the uterus. Sonohysterography can be performed in an office setting, hospital or clinic. If the fallopian tubes are evaluated a fluid containing bubbles of air are instilled through a catheter, bubbles make the fluid easier to see when assessing patency of the tubes. (ACOG, 2016). Tubal patency is determined by observing the saline and air contrast flowing into or out of each fallopian tube. There is a paucity of evidence evaluating sono-air HSG in the peer reviewed literature. One systematic review with meta-analysis evaluating the use of sono-HSG for evaluation of tubal occlusion was published in 2014, (Maheuz-Lacroix, et al., 2014). The authors assessed the accuracy of sono-HSG for diagnosing tubal occlusion in subfertile women. Although authors concluded that they observed high diagnostic accuracy of sono-HSG for tubal occlusion with overall sensitivity of 0.92 (95% CI: 0.82–0.96) and specificity of 0.95 (95% CI: 0.90–0.97) and also noted they found that the diagnostic accuracy of sono-HSG and HSG was comparable with no significant difference in performance of the two tests, all 28 studies included in this systematic used a flexible or rigid catheter for instillation of contrast and no study evaluated the use of the devices specifically indicated for sono-air HSG (e.g., femVue® [Femasys, Inc.]). Of note, only 6 studies included in the review evaluated saline +air as the contrast media, each study has small sample populations ranging from 31 subjects to 129 subjects. Of these 6 studies that utilized saline +air as the contrast media, three studies were a comparison of sono-HSG with the gold standard test for evaluation of tubal pregnancy, HSG. At present the evidence is insufficient to support the clinical utility of sono-air HSG.

In 2015 the ASRM published updated recommendations for evaluation of the infertile female. Within these recommendations although post coital testing is often performed to evaluate cervical factor infertility, it is no longer recommended as part of the routine evaluation of an infertile female (ASRM, 2015). The practice committee concluded “the test is subjective, has poor reproducibility, typically does not impact clinical management, and does not predict inability to conceive”. Similarly, endometrial biopsy has been used evaluate secretory development of the endometrium, dating, and to assess the quality of luteal function (e.g., luteal phase deficiency). However, this test is no longer recommended by the ASRM as it is not considered a valid diagnostic tool; the test lacks accuracy and precision, and cannot distinguish between fertile and infertile women (ASRM, 2015). According to the ASRM recommendations, its’ use should be reserved for conditions where endometrial pathology is strongly suspected.

Following the physical examination, evaluation of the male begins with the semen analysis, considered the primary screening test for male factor infertility. Semen analysis is generally done through the examination of two specimens at least one month apart (AUA/ASRM, 2020), and generally precedes invasive testing of the female partner. The semen analysis provides detailed information on semen volume, sperm concentration, motility, pH, fructose, leukocytes, and morphology. Depending on the clinical situation, repeat semen analyses may be performed every one to three months, up to a total of five. Performing greater than five semen analyses provides little additional diagnostic value. Other laboratory studies include an endocrine evaluation, antisperm antibodies, post-ejaculatory urinalysis, urine culture and semen culture. Additional testing includes:

- transrectal ultrasound in individuals with azoospermia or oligospermia
- scrotal ultrasound for individuals in whom testicular mass is suspected or for who physical exam is difficult/inconclusive
- vasography or testicular biopsy in individuals with azoospermia
- scrotal exploration

Genetic testing for cystic fibrosis is performed in males with congenital absence of vas deferens or for males with azoospermia or severe oligospermia (i.e., < 5 million sperm/millimeter) with palpable vas deferens. Karyotyping for chromosomal abnormalities and Y-chromosome deletion testing may be done in individuals with nonobstructive azoospermia or severe oligospermia.

Immunological factors may adversely affect fertility. As a result, various testing and treatment modalities have been proposed including, but not limited to, natural killer cell testing, antiphospholipid antibodies, antiprothrombin antibodies, embryotoxicity assay, and immune treatments such as pre-implantation glucocorticoids, anti-tumor necrosis factor agents (infliximab, etanercept), leukocyte immunization and IV immunoglobulin therapy. Nonetheless, evidence in the published, scientific literature is insufficient to support improved individual clinical outcomes (Royal College of Obstetricians and Gynaecologists [RCOG], 2003; RCOG, 2008).

Categories of other immunological tests such as immunophenotype measuring are also under investigation. Reproductive immunophenotype identifies the percentage of lymphocyte types in the blood. Analysis of subsets of lymphocyte types, such as CD-3, CD-4, CD-8, CD-19, CD-5, CD56, CD16 may be recommended for women with unexplained infertility or who fail to conceive after IVF. In theory, disturbances in the proportions of lymphocyte types may be related to reproductive failure. Evidence in the published scientific literature however evaluating the immunophenotype measurements is insufficient and the predictive value these tests are not clearly established (Baczowski, et al., 2007; Ghazeeri and Kutteh, 2001).

T1 and T2 Helper cell ratios have been investigated as a cause of infertility and recurrent pregnancy loss, however evidence in the peer-reviewed published scientific literature supporting clinical utility for T1:T2 Helper ratio testing is lacking (Ozkan, et al, 2014; Kwak Kim, et al., 2005).

Methods of predicting fertility potential continue to be researched. Oocyte quality and number decrease with age and determining ovarian reserve may add prognostic value for couples seeking assisted reproductive technologies. Early follicular phase FSH remains the most commonly used marker for determining ovarian reserve, other tests such as antral follicle count, and clomid challenge tests are well-established. Serum inhibin B is an enzyme immunoassay being investigated as a method of evaluating function of the antral follicles of the ovaries in women or the Sertoli cells of the testes in men. However, it has been reported in the literature that there is no international assay standard, and both follicular and recombinant standards are used, and that testing is not readily available (Creus, et al., 2000). The role of inhibin B for predicting pregnancy is unclear. At present, there is insufficient evidence in the published literature to support serum inhibin B testing as a predictive marker of ovarian response (Lukaszuk, et al., 2013; ASRM, 2012d; RCOG, 2004; Creus, et al., 2000; Corson et al., 1999).

Anti-mullerian hormone (AMH), produced by granulosa cells from preantral and early antral follicles, has also been evaluated as a predictor of ovarian reserve (Lukaszuk, et al., 2013; Brodin, et al., 2013; Ankaert, et al., 2012; Kunt, et al., 2011; A La Marca, et al., 2011; Steiner, et al, 2011; Tremellen, et al., 2010; Kini, et al., 2010; Steiner, 2009; Kaya, et al., 2010; Guerif, et al., 2009). Authors generally agree the decline of ovarian reserve with aging is associated with a decrease in anti-mullerian hormone levels. Nonetheless there appears to be little consensus regarding a specific value of serum anti-mullerian hormone for defining those women who may respond poorly to assisted reproductive technologies such as in vitro fertilization. According to the ASRM (2020) serum concentrations of anti-mullerian hormone remain consistent within and between menstrual cycles in both young ovulating and infertile women and levels can be obtained on any day of the menstrual cycle. Levels lower than 1 ng/ml have been associated with less than optimal responses to stimulation of the ovaries, poor embryo quality and poor pregnancy outcomes in IVF (ASRM, 2020). Evidence supporting improved clinical outcomes as a result of testing is mixed; some authors have reported strong predictive value, sensitivity and specificity, while others have not. According to the ASRM (2020) there is evidence to support that low levels of AMH have high

specificity for poor ovarian response, therefore testing may help predict response to ovarian stimulation. However evidence to support use for screening of a woman's ability to conceive is lacking. Serum AMH testing is recommended for select woman at increased risk of ovarian reserve, including any of the following:

- women over age 35
- family history of early menopause
- women with a single ovary or history of previous ovarian surgery, chemotherapy, or pelvic radiation therapy, woman who have unexplained infertility
- women who have had a poor response to gonadotropin stimulation
- women who are planning treatment with assisted reproductive technologies (e.g., IVF).

Endometrial receptivity and the relationship to infertility, particularly for IVF cycles, is another area that is being investigated. Traditionally, researchers have used the endometrial biopsy as a method of assessing components of the endometrium. Researchers have evaluated a series of markers that can potentially be used to assess the functional state of the endometrium. The endometrial receptivity array (ERA), a genomic diagnostic tool based on microarray technology, is under investigation as an endometrial receptivity marker (Diaz-Gimeno, et al., 2011). Cyclin E and p27 have been identified as markers of endometrial receptivity and predictors of successful implantation (Dubowy, et al., 2003; Kliman, et al., 2000). A test recently developed that can assess the expression of cyclin E and p27 is the Endometrial Function Test™ (EFT®) (Yale University School of Medicine, New Haven, CT). While some authors contend these tests may have a role in evaluating the endometrial receptivity, studies are limited, and the benefits of endometrial function testing in predicting pregnancy outcomes have not been established. Expression of integrins has been studied by some authors and may be associated with endometriosis and unexplained infertility; although the data is limited, it is not conclusive, and further study is needed (Thomas, et al, 2003, Bourgain and Devroey, 2003).

Vaginal microbiome testing is a method of testing under evaluation and investigation. Imbalances of vaginal flora may lead to vaginal/pelvic infection and possibly reproductive complications. One vaginal microbiome test, SmartJane™ (uBiome, Inc.) is a sequencing based screening test purported by the manufacturer that genotypes 14 high-risk HPV strains, 5 low-risk HPV strains, 4 common sexually transmitted diseases (STIs) (i.e, chlamydia, gonorrhea, syphilis, mycoplasma genitalium) and measures 23 other vaginal flora. Once the test is ordered by a physician, a sample is collected in the home which is then mailed to a uBiome laboratory where it is processed. Results are subsequently made available to the patient and their physician electronically and may potentially contribute to diagnosis, treatment and monitoring of conditions that can affect vaginal health. Published evidence in the medical literature is insufficient to support the validity, clinical utility, and improvement of net health outcomes for vaginal microbiome testing at this time and the implication of testing in infertility requires additional research to support its use.

The clinical utility of the tests noted below has not been demonstrated in the medical literature. These tests have been proposed for a select subset of patients to identify a male factor contributing to unexplained infertility or in the treatment of infertility to select specific interventions. In general, they are reserved for those individuals for whom identification of the underlying cause of male infertility will direct specific treatment modalities.

- Sperm viability test (hypo-osmotic swelling test): This test is used to determine if non-motile sperm are viable and may be done to determine if intracytoplasmic sperm injection (ICSI) is an option for treatment. The role of assessing sperm viability using the hypo-osmotic method in the diagnosis or treatment of infertility has not been established in the published, peer-reviewed scientific literature.
- Zona-free hamster oocyte test (sperm penetration assay): This test is generally reserved for patients in whom results will influence treatment strategy (American Urological Association [AUA] 2011[a]). It is used to assess the ability of spermatozoa to undergo capacitation (egg penetration) and achieve fertilization (Bradshaw, 1998). Evidence in the scientific literature has suggested a correlation between results of this test and in both vitro fertilization (IVF) cycles and intracytoplasmic sperm injection (ICSI).
- Hyaluronan binding assay (HBA): This test has been proposed as an additional evaluation tool to determine the maturity of sperm in a fresh semen sample. The assay is based on the ability of the mature sperm to bind to hyaluronan, a component of the external coating of the ova. It has been

suggested that HBA may prove useful in determining a need for intracytoplasmic sperm injection; however, evidence in the published literature has not confirmed HBA can provide additional information over standard semen analysis for sperm-fertilizing ability.

- Hemizona test: This test assesses the ability of the sperm to bind to the zona pellucida. Like the sperm penetration assay, preliminary studies have suggested a correlation with in vitro fertilization outcomes. The role of this test in the diagnosis or treatment of infertility has not been established in the published, peer-reviewed scientific literature.
- Computer-assisted motion analysis: Time-lapsed photography, video micrography and computer-assisted motion analysis are techniques used to determine sperm velocity and linearity. Proponents of the computer-based method contend that it allows for the measurement of more sophisticated parameters such as lateral head displacement and flagellar beat frequency. There is insufficient evidence in the published, peer-reviewed scientific literature to support the use of this technology in the diagnosis or treatment of infertility.
- Sperm DNA integrity testing: It is theorized that sperm DNA damage may affect reproductive outcomes in select couples, and several tests for sperm DNA integrity are now available (e.g., Sperm Chromatin Structure Assay [SCSA], TUNEL assay, Comet assay). Another test to assess sperm DNA is the Sperm DNA Decondensation test (e.g., Human Sperm Activation Assay [HSAA], SDD™). Current methods for evaluating sperm DNA integrity do not reliably predict treatment outcomes, and no treatment for abnormal DNA integrity has proven clinical value. The AUA (2011a) reported that the assays demonstrate low sensitivity and high specificity. In 2015 the ASRM reported in their committee opinion regarding the diagnostic evaluation of the infertile male that DNA integrity testing is controversial because the prognostic clinical value may not affect treatment of couples (ASRM, 2015).
- Reactive oxygen species: Reactive oxygen species (ROS) may interfere with sperm function and are generated by both seminal leukocytes and sperm cells. ROS have a normal physiological role in the capacitation and acrosome reaction and as such have been implicated as a cause of male factor infertility. Controversy exists regarding best methods of testing, the role of excess ROS in natural conception as well as reproductive technologies, and whether therapies are effective for improving clinical outcomes. Furthermore, there is insufficient published data to support ROS testing in the management of male factor infertility (AUA, 2011[a]). In 2015 the ASRM reported in their committee opinion regarding the diagnostic evaluation of the infertile male that ROS has a very limited role in the evaluation of male infertility (ASRM, 2015).
- Sperm capacitation assay assessment: Capacitation is the process sperm must undergo that involves biochemical alterations which then allow the sperm to penetrate and fertilize the egg. The ability of sperm to undergo capacitation has been evaluated and reported on in the medical literature. One method to evaluate sperm capacitation is “Cap-Score” (Androvia LifeSciences, Mountainside, New Jersey) which is a proprietary biomarker-based test to measure the sperm's ability to penetrate and fertilize an egg. More specifically, according to the manufacturer the test “measures the fundamental biological process that controls fertility and does so by proprietary technology that assesses the sperm's capacity to fertilize an egg. Cap-Score detects and analyzes localization patterns using fluorescent microscopy to distinguish fertile from infertile sperm cells, and those capable of going on to generate a pregnancy from those that cannot.” Conducting a Cap-Score test involves the incubation of sperm in non-capacitating (Non-Cap) medium and medium containing capacitating stimuli (Cap). The sperm that respond to the capacitation stimuli are identified by specific GM1 localization patterns. The final readout—the “Cap-Score”—reports the proportion of sperm within a sample that displays the localization patterns that correspond with capacitation. Sperm capacitating assays are an emerging technology with evidence in the peer reviewed scientific literature evaluating sperm capacitation assays primarily in the form of observation or cohort studies; randomized controlled trials, systematic reviews and/or meta-analyses are lacking. In addition, the ASRM and AUA do not address sperm capacitation assays within their formal position statements and Practice Committee Opinions. Due to the paucity of evidence in the medical literature strong evidence based conclusions cannot be made regarding the clinical utility of this type of testing.

Treatment of Female Infertility Factors

Treatment of infertility typically begins with the confirmed diagnosis of infertility. Treatment is determined by the specific diagnosis and may involve oral or injectable medication, surgery, assisted reproductive technologies, or a combination of these. Infertility may be the result of endometriosis, tubal factors, uterine and endometrial factors, cervical factors, ovulatory factors, or from unexplained factors. Pharmacologic and other medical treatment is typically attempted before more invasive interventions are sought.

Endometriosis: Endometriosis is the presence and growth of glands and stroma identical to the lining of the uterus in an unusual location. It is often associated with pelvic pain and infertility, although some individuals may be asymptomatic. The short-term goals of treatment include reduction of pelvic pain and promotion of fertility while long-term goals include halting the progression or recurrence of disease. Treatment usually consists of pharmacologic therapy, surgery or a combination of both. Pharmacologic therapy includes oral contraceptives, danazol, medroxyprogesterone acetate, and gonadotropin releasing hormone agonists. Surgical treatment involves the resection or destruction of endometrial implants, lysis of adhesions, and attempts to restore normal pelvic anatomy either through a laparoscopic approach or open laparotomy (Lobo, 2012a). Pelvic adhesions can lead to decreased mobility and function, affecting the biomechanics of the pelvic organs and may lead to infertility. Manual soft-tissue therapy (e.g., Wurn Technique[®], Clear passage therapy) has been proposed as a method of breaking down the adhesions and improving elasticity, increasing pregnancy rates. The published data evaluating this technique is limited (Wurn, et al, 2008; Wurn, et al., 2004) and the safety and efficacy of soft-tissue therapy as a method of treatment for infertility has not been established in the peer-reviewed medical literature.

Tubal Factors: There are numerous causes of tubal disorders, including: prior salpingitis (pelvic inflammatory disease and other causes), endometriosis, adhesions from prior surgery, complications of intrauterine devices, and prior ectopic pregnancy. Lysis of mild peritubal adhesions may be performed during laparoscopy; however, many patients will only achieve pregnancy after tuboplasty or in vitro fertilization and embryo transfer. Tubal infertility factors can also be related to previous voluntary sterilization procedures, such as tubal ligation.

Several methods are available to treat infertility related to tubal factors. Tubal recanalization is performed when adhesions or endometriosis occlude the fallopian tubes. Other treatments include salpingostomy, fimbrioplasty, tubal anastomosis, fluoroscopic/hysteroscopic selective tube cannulation, and salpingectomy. While this method is rather obsolete, low tubal ovum transfer (LTOT) is a method in which an ovum is retrieved from the ovary and inserted in the uterus near the uterotubal junction bypassing the blocked fallopian tube. These procedures are also performed to treat infertility that is the result of voluntary sterilization.

Uterine and Endometrial Factors: Uterine and endometrial factors which may contribute to infertility include tumors/myomas, congenital malformations such as septate uterus, endometriosis and adhesions.

Treatments of uterine and endometrial factors include the following:

- treatment of myomas: hysteroscopic removal of submucous myoma; myomectomy for intramural or other myomas
- repair of congenital malformations: repair of septate uterus may be performed via hysteroscopy or laparotomy
- treatment of uterine adhesions: lysis of adhesions performed via dilatation and curettage or hysteroscopy

Uterine transplantation is under investigation as a method of offering fertility options to women who have uterine factor infertility, whether congenital (e.g., Mullerian malformations) or acquired (e.g., Asherman's syndrome, intrauterine myomas). Live births have been reported following uterine transplantation, and donors in most cases have been live donors with few reports of deceased donors in the literature. Similar to other organ transplants, risk of rejection is a complication; higher doses of immunosuppressive agents, known to cross the placental barrier, are often required in pregnancy and pose additional risks. General recommendations currently indicate that as part of a pre-determined plan following completion of one or two successful pregnancies the uterus is then removed to limit the immunosuppression period. A position statement from the American Society of

Reproductive Medicine was published in 2018. The ASRM position statement recognizes uterus transplantation as a successful medical treatment of absolute uterus factor infertility, while cautioning health professionals, patient advocacy groups and the public about its highly experimental nature. Uterus transplantation is considered an experimental treatment (ASRM 2018).

Cervical Factors: Cervical factors may also account for infertility, and primarily consist of abnormalities of the cervical mucus or a cervical stenosis. The quality of cervical mucus in many cases cannot be corrected through the use of pharmacologic agents (e.g., estrogen) and intrauterine insemination is recommended. In cases involving cervical infections, antibiotics are prescribed. Cervical stenosis may be corrected by hysteroscopy and cervical recanalization.

Ovulatory Factors: Ovulatory dysfunction is a frequent cause of female infertility. Ovulation may be absent or occur irregularly due to ovary abnormalities or abnormal secretion of the hormones needed to support ovulation. Typically, fertility begins to decrease in women during the early- to mid- thirties. The standard test for determining decreased ovarian function is a day-3 follicle stimulating hormone (FSH) level. Normal day-3 FSH values vary among laboratories and specific assays; however, decreased ovarian function is seen with a level greater than 10–15 IU/L. Although some women with elevated day-3 FSH levels may become pregnant, the chance of establishing a pregnancy even with the use of in vitro fertilization (IVF) is markedly reduced.

Ovulatory dysfunction may also be related to diseases not directly linked to the reproductive system, such as medications, addictive drugs, weight loss, obesity, and psychological factors. Induction of ovulation through the use of pharmacotherapeutic agents is generally the first-line approach to treat conditions that prevent ovulation. Ovulation induction is also used as an adjunct to assisted reproductive techniques and intrauterine insemination. Originally, ovarian wedge resection was performed for patients with polycystic ovarian (PCO) syndrome who did not respond to drug treatment. Currently, surgical treatment of PCO with partial ovarian destruction utilizing electrocautery or laser, referred to as ovarian drilling, has been utilized in women when clomid has failed to induce ovulation. During this procedure, several punctures are made through the surface of the ovary with a needle and coagulated. Ovulatory cycles generally resume and androgen levels become normal. If ovulation does not occur spontaneously, most anovulatory women will ovulate with clomid.

The following drugs have been shown to induce ovulation:

- Clomiphene citrate, an oral synthetic nonsteroidal estrogen agonist-antagonist, enhances the release of pituitary gonadotropins resulting in follicular development and rupture.
- Gonadotropins, including but not limited to human menopausal gonadotropins (hMG) (e.g., Pergonal[®], Repronex[®], LH and FSH), human chorionic gonadotropin (HCG) (e.g., Pregnyl[®], Novarel[™]), human FSH, and recombinant FSH/follitropins (e.g., Follistim[®], Gonal-F[®]) may be administered to patients who have not responded to clomiphene
- Gonadotropin-releasing hormone (GnRH) (e.g., leuprolide, goserelin) is an alternative to gonadotropins in cases of low gonadotropin and estrogen levels. The drug is delivered intravenously or subcutaneously with the use of a computerized pump. One advantage of this pulsatile GnRH therapy over gonadotropin therapy is the reduced risk for multiple conception and ovarian hyperstimulation.
- Bromocriptine is an oral dopamine agonist used as the initial intervention for women with hyperprolactinemia and anovulation, oligo-ovulation, or luteal phase insufficiency.
- Metformin, an insulin sensitizing drug, may be considered in women with polycystic ovarian syndrome although its use should be restricted to those with glucose intolerance.

Emerging treatments for infertility that are currently under investigation include the use of acupuncture to improve live birth rates, intrauterine injection of platelet rich plasma to improve endometrial quality and implantation rates, and physiological, hyaluronan-based selection of sperm (PICSI) to improve live birth rates and decrease miscarriage rates. Nevertheless, well-designed clinical trials with rigorous methodological quality are needed to firmly establish the clinical utility of these emerging treatments.

Treatment of Male Infertility Factors

Obstructive/Nonobstructive Azoospermia: Azoospermia is defined as a complete absence of sperm from at least two separate centrifuged semen samples (AUA, 2011[b]). It may be caused by obstruction of the extratesticular ductal system (obstructive azoospermia) or defects in spermatogenesis (nonobstructive azoospermia). Obstructive azoospermia may be congenital or acquired, and may be caused by epididymal, vas deferens, or ejaculatory pathology. Acquired causes of azoospermia include previous vasectomy, genitourinary infection, scrotal or inguinal injury and congenital anomalies. Treatment of obstructive azoospermia, when performed in order to achieve pregnancy, includes: surgical correction of the obstruction, which provides the ability to produce pregnancy by intercourse; or retrieval of sperm from the male reproductive system for IVF and ICSI.

Surgical repair of obstruction can be achieved by:

- surgical/microsurgical reconstruction of the vas and/or epididymis, including vasectomy reversal, epididymovasostomy, epididymectomy, vasovasostomy; or
- transurethral resection of the ejaculatory ducts (TURED) when there is ejaculatory duct obstruction

Sperm retrieval and cryopreservation may be performed at the time of microsurgical reconstruction in order to avoid a second procedure in the event that the microsurgical reconstruction does not reverse a patient's azoospermia (ASRM, 2019).

Males with nonobstructive azoospermia should have genetic testing before proceeding to assisted reproductive technologies, such as in vitro fertilization with intracytoplasmic sperm injection. Genetic disorders may be characterized as karyotype abnormalities. In some men, microdeletions of the Y chromosome contribute to azoospermia. Male offspring born to fathers of Y-chromosome microdeletion are expected to inherit these deletions. As such, genetic/clinical counseling regarding genetic issues should be considered a critical part of the male evaluation (Brugh, 2003; Society of Obstetricians and Gynaecologists of Canada (SOGC), Okun, Sierra, 2014).

Abnormalities of Ejaculation: Ejaculatory dysfunction may be associated with male factor infertility. Abnormalities of ejaculation may be caused by neurologic, anatomic or psychological abnormalities. Retrograde ejaculation is caused by incomplete closure of the bladder neck. For this condition, sperm may be obtained from the postejaculatory urine. Anejaculation is often due to spinal cord injury or other neurologic impairment (e.g., retroperitoneal surgery, trauma, diabetes). Treatment options may be medical or surgical. Options for sperm retrieval may include vibratory stimulation, electroejaculation or surgical retrieval. These techniques are often associated with poor sperm quality and, in most cases recovered sperm are used for intrauterine insemination (IUI), IVF or ICSI cycles (Schuster, Ohl, 2002).

Seminal Tract Washout (STW): STW is a technique involving the cannulation of the vas deferens and subsequent antegrade washing of the vas with collection of sperm from the bladder. STW may be used in situations where male infertility is due to incomplete voiding of the distal seminal tract, and spermatozoa can be retained downstream of the epididymis. Common conditions include diabetes, spinal cord injury, and extended retroperitoneal lymph node dissection.

Other Procedures: Other procedures used to treat male factor infertility include:

- repair of varicocele (dilatation of the pampiniform plexus of the scrotal veins), including spermatic vein ligation (retroperitoneal, inguinal, laparoscopic or scrotal), spermatic vein embolization (balloon, coils, sclerosing agents, or transcather/transvenous occlusion), excision of spermatocele, orchiopexy
- treatment of endocrinopathies including:
 - hypogonadotropic hypogonadism: stimulation of secondary sexual characteristics and normal spermatogenesis through the use of HCG and hMG or pulsatile GnRH
 - disorders of LH or FSH function: treatment includes replacement of FSH and HCG
 - disorders of androgen function: treatment includes corticosteroids, mineralcorticosteroids, or androgens
 - medical and surgical treatment of adenomas of the pituitary gland
- excision of epididymal tumor

Sperm Precursors: There is insufficient evidence in the published, peer-reviewed scientific literature to support the use of sperm precursors (round or elongated spermatid nuclei, immature sperm) in the treatment of infertility with ICSI.

Treatment of Unexplained Infertility

Of couples experiencing infertility up to 30% are diagnosed with unexplained infertility (ASRM, 2020). For these couples the infertility workup will not reveal any abnormalities. There is no specific treatment for unexplained infertility, but assisted reproductive technologies are sometimes pursued.

Treatment for unexplained infertility includes ovarian stimulation with timed intercourse, ovarian stimulation and intrauterine insemination (IUI), unstimulated intrauterine insemination (i.e., natural cycle IUI), and for some assisted reproductive technologies.

Within evidence-based guidelines published by the ASRM (2020) for couples with unexplained infertility the ASRM recommends the following:

- Clomiphene citrate with IUI
- Letrozole with IUI, as an alternative regimen to clomiphene citrate
- A single IUI be performed between 0-36 hours relative to hCG injection during ovarian stimulation/IUI cycles
- A course of 3-4 cycles of ovarian stimulation/IUI with oral agents, if unsuccessful followed by ovarian stimulation with IVF cycles rather than ovarian stimulation/IUI cycles with gonadotropins

The ASRM does not recommend the following as they are not more effective than expected management:

- natural cycle IUI, as it is less effective than ovarian stimulation with IUI
- Clomiphene citrate with timed intercourse
- Letrozole with timed intercourse
- use of gonadotropins with timed intercourse
- Letrozole or clomiphene citrate with conventional gonadotropins with IUI
- Low-dose or conventional-dose gonadotropins with IUI

Artificial Insemination

Artificial insemination (AI) is a procedure in which sperm are placed in the cervix or high in the uterine cavity through a transcervical catheter. The rationale is to deposit sperm as close to the oocyte as possible. A trial intrauterine insemination (IUI), also referred to as mock IUI, is a procedure performed solely to assess the cervix and uterus prior to the IUI, however trial/mock IUI is considered an integral part of the IUI procedure. AI, intrauterine insemination (IUI), or intracervical insemination (ICI) may be performed using either the partner's sperm or donor sperm. Artificial insemination may be preceded by ovarian stimulation with gonadotropins or clomiphene to encourage multiple oocyte development, especially in cases of unexplained infertility. AI techniques are typically attempted for up to six cycles before proceeding to more complex interventions such as in vitro fertilization.

Other methods of insemination less frequently employed include direct intraperitoneal insemination (DIPI), intrafollicular insemination, (IFI), and fallopian tubal sperm perfusion (FSP). DIPI has not been shown to be more effective than IUI/ICI and is a more invasive method. IFI is a method of injecting motile sperm directly into the pre-ovulatory follicle. It is suggested that fertilization occurs prior to ovulation and the presence of follicular factors may provide stability to the fertilized egg. FSP increases the number of motile sperm in the fallopian tube. These methods are not widely used, and there is insufficient evidence in the published literature regarding efficacy. Reported outcomes have been inconsistent, and they have not been proven in large, well-designed studies to increase pregnancy rates compared to AI.

Superovulation with intrauterine insemination involves the intentional development and ovulation of multiple follicles.

Indications for artificial insemination:

- * pharmacologic treatment alone has not been successful
- * unexplained infertility
- * abnormal cervical mucus
- * donor insemination
- * presence of antisperm antibodies
- * low sperm counts with normal motility

Assisted Reproductive Technologies

Assisted reproductive technologies (ART) describe a group of infertility treatment procedures that involve the extracorporeal manipulation of both oocytes and sperm, and/or embryos. Techniques include: in vitro fertilization with embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and intracytoplasmic sperm injection (ICSI). In addition, technologies such as co-culturing of embryos, assisted embryo hatching and Kruger's "strict criteria" for assessing sperm morphology may be recommended as part of an IVF cycle.

In Vitro Fertilization with Embryo Transfer (IVF-ET): IVF is a procedure that involves removing eggs from the ovaries and fertilizing them outside the body. The resulting embryos are then transferred into the uterus through the cervix. For the purpose of this Coverage Policy, an IVF cycle ending with embryo implantation is considered an attempt at IVF, whether there is one or more than one embryo implanted during that event. Additional embryo implantations would be considered a second IVF attempt or IVF cycle, whether those embryos were frozen or not. An embryo transfer that is unsuccessful in resulting in a pregnancy is considered a failed IVF attempt.

The success rate of IVF has been reported to be approximately 22.8% live births per egg retrieval. This is similar to the 20% chance that a healthy couple has of achieving a pregnancy that results in a live birth in a given month.

The steps involved in IVF are as follows:

1. Ovarian stimulation/hyperstimulation and monitoring.
2. Egg retrieval: After the follicle has ruptured, the physician removes multiple eggs transvaginally or by laparoscopy.
3. Fertilization: A semen sample from the male partner or donor is processed using sperm washing, in which active sperm are selected. Mature egg cells are combined with the selected sperm and cultured for approximately forty hours. Forty-six to fifty hours after egg retrieval, fertilization and cell division are evaluated. Two to six fertilized embryos are selected. Embryos may also be cryopreserved at this point for later use.
4. Embryo transfer: The selected fertilized embryos are placed in a catheter, combined with a transfer growth medium, and inserted through the patient's vagina and cervix into the uterus. It is believed the transfer medium promotes implantation of the embryo and varies according to clinic; however, the most common protein used is synthetic albumin; other additives have been investigated (e.g., hyaluronan, EmbryoGlue®), but improvement in embryo development and implantation has not been clearly established in the published literature.
5. Embryo cryopreservation: If there are embryos that are not needed for transfer in the current cycle, cryopreservation may be used. This is a process in which the embryos are frozen in liquid nitrogen and may be thawed for future use. A significant percentage of embryos do not survive the process of freezing and thawing, however. Cryopreservation may result in hardening of the zona pellucida which may affect hatching and implantation of blastocyst (Liu, et al. 2007). Some embryos lose one or more blastomeres after thawing and are referred to as "partially damaged" embryos. While partially damaged embryos can give rise to term pregnancy, authors agree that the developmental potential of these embryos is inferior

to those that are fully intact. Some authors have reported that laser-assisted removal of necrotic blastomeres from partially damaged cryopreserved embryos before embryo transfer increases embryo development potential (Liu, et al., 2007; Nagy, et al., 2005; Rienzi, et al; 2005, Rienzi 2002). However, while outcomes are encouraging regarding implantation and pregnancy rates, there is insufficient evidence in the peer-reviewed scientific literature regarding the safety and efficacy of the use of laser-assisted necrotic blastomere removal from cryopreserved embryos.

In many cases, assessment of the cervical canal and uterus is performed prior to an actual embryo transfer. A mock embryo transfer employs the use of a thin plastic catheter, without an embryo, that is passed through the cervix and into the uterus to evaluate the potential for embryo transfer. A second method, uterine sounding, employs the use of an instrument referred to as a uterine sound to determine depth and direction of the uterus prior to embryo transfer.

In natural cycle IVF or natural oocyte retrieval IVF, there is no hyperstimulation with ovulation induction drugs. Ovulation is allowed to occur naturally without intervention.

For standard IVF cycles, when fertilization occurs, the developing embryos are incubated for 2–3 days in culture and then placed into the uterus. In some cycles, embryos are cultured for 5–6 days (i.e., extended culture) and then transferred into the uterus at the blastocyst stage using a single medium, or in some cases two distinct media. During the natural process of embryo development, when the embryo reaches the blastocyst stage (i.e., 6–7 days after fertilization) it is ready for implantation. Although reliable criteria to identify embryos that may develop to blastocyst stage has not been established, according to the ASRM Practice Committee, some of the theoretical advantages of growing embryos to the blastocyst stage include higher implantation rates, a decrease in the number of embryos transferred, the opportunity to select more viable embryos, better synchronization of embryo and endometrial readiness, and the opportunity to perform preimplantation genetic diagnosis as a result of increased culture time (ASRM, 2008a). Evidence in the published literature indicates that transfer on day two or three and day five or six appear to be equally effective in terms of increased pregnancy and live birthrate rates per cycle started (Blake, et al., 2006; National Institute of Health and Clinical Excellence [NHS], 2004). Evidence can also be found suggesting (more specifically) that when an equal number of embryos are transferred, the probability of live birth rate after fresh IVF is significantly higher after blastocyst-stage transfer compared to cleavage-stage transfer (Papanikolaou, et al., 2008). Conclusions from the ASRM Practice Committee (2018) indicate the following that in patients with good prognosis, the transfer of blastocysts has been observed to yield higher live birth rates than those achieved with transfer of equal numbers of cleavage-stage embryos. Due to high implantation rates with blastocysts elective single embryo transfer should routinely be used to minimize multiple gestation.

Tubal embryo transfer (TET) or pronuclear stage transfer (PROST), and tubal embryo stage transfer (TEST), are also considered variations of standard IVF-ET and involve transfer of embryos into the fallopian tubes at different stages. TET is similar to ZIFT, except the embryos are transferred 8–72 hours after fertilization.

Indications for IVF include the following:

- * blocked or severely damaged fallopian tubes
- * endometriosis
- * male factor infertility
- * failed six cycles of ovarian stimulation with intrauterine insemination
- * unexplained infertility of long duration with failure of other treatments

Methods proposed for improving IVF success rates include the following:

- Co-culture of Embryos: Co-culturing of embryos is the culturing of embryos on a layer of cells that in theory, removes toxic substances produced by the embryo. It is a technique currently under investigation aimed at improving the quality of embryos and involves the use of various cell-lines. It may be recommended for individuals who have un-successful IVF cycles and poor quality embryos. Authors have identified various techniques of co-culturing of embryos (Kervancioglu, et al., 1997; Wiemer, et al., 1998; Rubio, et al., 2000). However, co-culturing of embryos using feeder cells (e.g., granulosa,

endometrial, tubal) in order to improve implantation success has not been demonstrated in the published, peer-reviewed scientific literature to improve implantation or pregnancy rates. The role of this technique in the treatment of infertility has not been established.

- **Assisted Embryo Hatching:** Assisted zona hatching is the artificial thinning or breachment of the zona pellucida such that an embryo that develops to the blastocyst stage can expand through the confines of the pellucida allowing the otherwise normal embryo to make contact with the endometrial lining and implant. It has been suggested by some studies that thick and hardened zona may prevent or reduce the efficiency of hatching of otherwise normal developing embryos. Thick or hardened zona may result from gonadotropin stimulation, the laboratory environment, culture techniques, age > 38, or with elevated day-3 FSH levels (Richlin, et al, 2003). The use of assisted hatching has been proposed as a method to facilitate implantation and pregnancy rates. It may be performed in conjunction with IVF, ZIFT, and ICSI to enhance the probability of achieving pregnancy. The procedure is typically performed on day three, five or six, and involves creating a gap in the zona by drilling with an acidified medium, partial zona dissection with a glass microneedle, laser photoablation, or use of a piezo-micromanipulator. Evidence in the published, peer-reviewed scientific literature has yielded few randomized clinical studies, inconsistent success rates, and no specific patient selection criteria. Although assisted hatching may facilitate implantation it is used selectively for cases of poor prognosis (repeated IVF failure, embryos of poor quality, thick zona, etc.). The Practice Committee of the ASRM (2014) reported, "The routine use of assisted hatching in the treatment of all IVF patients should not be recommended. Assisted hatching may be clinically useful in patients with a poor prognosis, including those with ≥ 2 failed IVF cycles and poor embryo quality. According to published text (Richlin, et al., 2003), the indications for assisted hatching include: age greater than 38, elevated day-3 FSH, a prior failed IVF cycle with suspected implantation failure, increased zona thickness on microscopy, and excess oocyte fragmentation.
- **Kruger's Strict Criteria for Sperm Morphology:** Sperm morphology has become a useful indicator of successful fertilization with IVF. Kruger coined the term "strict criteria," which involves the identification and use of only those sperm which are determined to be morphologically normal. In studies using strict morphologic criteria, men with greater than 14% normal forms had normal fertilization rates in vitro. Patients with 4–14% normal forms had intermediate fertilization rates, while men with less than 4% normal forms had fertilization rates of 7–8%. The identification of sperm morphology using Kruger's strict criteria is considered an integral part of the sperm analysis prior to IVF. According to the AUA (2011a) strict criteria should not be used in isolation to make prognostic or therapeutic decisions.
- **Time-lapse Monitoring:** Time-lapse monitoring/imaging is a noninvasive method of embryo evaluation that allows 24-hour monitoring of embryo development. Although stable, controlled incubation systems are necessary for embryo development, conventional methods to assess embryos in IVF cycles are based on daily evaluation of morphology via a microscope, after removal from standard incubators at a defined point in time. Authors hypothesize time-lapsed monitoring, embryo assessment conducted without disturbance to the culture conditions and removal from the incubator, improves the quality and quantity of information regarding embryonic cleavages and morphologic assessment. Time-lapsed monitoring is purported to refine embryo selection, and thereby improve IVF clinical pregnancy rates (Rubio, et al., 2014). One device, the EmbryoScope® Time-Lapse System (Vitrolife, Inc., Englewood, CO) provides a time-lapse video with thousands of snapshots of each embryo over three to five days of in vitro culture. A second test currently FDA approved and available is the Early Embryo Viability Assessment (Eeva™) test (Auxygn, Inc.) While time-lapse monitoring may allow more detailed observations of embryonic development, there is insufficient evidence in the peer-reviewed published scientific literature supporting clinical utility, improved IVF outcomes, and improved pregnancy rates with the use of this technology.

Intravaginal Culture/Incubation: Although further study is required to support clinical efficacy, intravaginal culture of oocytes and sperm has been proposed as an alternative to conventional IVF. During this procedure, a small gas-permeable plastic device containing oocytes and sperm is placed into the vagina where fertilization and subsequent embryo development occurs during a three day incubation. The device is then removed; embryos are selected and then transferred into the uterus under ultrasound guidance. Use of the device simplifies the IVF procedure in that laboratory and embryologist-related services are reduced in addition to

allowing fertilization to occur in the female reproductive tract which provides the pCO₂, pO₂, and temperature for culturing. Preliminary trials have supported clinical pregnancy rates that are comparable to conventional IVF cycles (Doody, et al., 2016; Mitri, et al., 2015; Lucena, et al 2012) however sample populations are small and concerns remain regarding the potential for abnormal fertilization and the reduced ability to monitor embryo development prior to transfer.

Hyperbaric Oxygen Therapy (HBO): It has been proposed that increasing oxygenation by HBO may aid in egg maturation and alignment of chromosomes during meiosis but there insufficient evidence to report this claim.

Cryopreservation and In Vitro Maturation (IVM) of Immature Oocytes: In vitro maturation of oocytes is a procedure where immature oocytes are retrieved from follicles which may or may not have been exposed to exogenous FSH, have not been exposed to exogenous LH or HCG, and are then allowed to mature in culture. Theoretically, the oocytes mature and can be fertilized. A committee opinion by the ASRM (2021) indicates that IVM is no longer considered experimental and that potential candidates for IVM include women with PCOS or PCO type ovaries or those with ovarian hyperstimulation syndrome. The efficacy of IVM for estrogen-sensitive cancers, or in women with limited time for initiating fertility preservation before undergoing potentially gonadotoxic cancer treatments, however is still not clear according to the ASRM (2021). More specifically regarding cancer indications the ASRM cited literature indicating the reproductive potential of vitrified IVM oocytes is impaired owing to the vitrification-warming procedure in one study, and in another study the authors reported poor pregnancy and delivery outcomes from vitrified-thawed embryos derived from IVM oocytes for cancer patients. Furthermore, IVM of oocytes after recovery from thawed ovarian tissue frozen from postmenarchal versus premenarchal girls yielded decreased maturation rates in both groups (28.2% vs. 15.5%, respectively), which was further reduced in girls under 5 years of age (4.9%) (ASRM, 2021). It is the opinion of the ASRM that the procedure should only be offered by those with expertise gained by specific training, informed consent, and appropriate counseling about expected fertility preservation results (ASRM, 2021).

Gamete Intrafallopian Transfer (GIFT): The GIFT procedure is an alternative to IVF. In GIFT, the egg cells are retrieved laparoscopically and transferred to the fallopian tubes using a catheter containing 2–3 egg cells and approximately 100,000 sperm. Unfertilized oocytes are mixed with sperm and transferred back into the tubes. Fertilization occurs in the body as in unassisted reproduction, as compared to IVF in which fertilization occurs outside the body. Indications for GIFT are the same as for IVF, except that the woman must have one patent fallopian tube. GIFT has become exceedingly rare and is associated with increased risk to the patient due to the more invasive requirements for laparoscopy and increased risks of ectopic pregnancy. Current pregnancy rates for conventional in vitro fertilization are higher than GIFT.

Zygote Intrafallopian Transfer (ZIFT): ZIFT is another variation of IVF and GIFT without clear proven advantages. Following fertilization, which occurs in vitro, a one-cell zygote or pre-embryo is transferred into the fallopian tube. The pre-embryo then moves to the uterus by natural processes. ZIFT may be an option in rare situations when abnormality of the cervical canal prevents passage of an embryo transfer catheter into the uterus. Performance of ZIFT is also extremely rare, invasive, and is associated with increased risk to the patient. Furthermore, as noted above current pregnancy rates for conventional in vitro fertilization are higher than both GIFT and ZIFT.

Intracytoplasmic Sperm Injection (ICSI): ICSI is a laboratory procedure developed to assist couples who are undergoing IVF for severe male factor infertility. The ICSI procedure is used in conjunction with IVF, GIFT and ZIFT. This procedure has replaced two previously developed micromanipulation techniques, partial zona dissection (PZD) and subzonal insertion (SUZI) because it achieves higher fertilization rates. ICSI involves the injection of a single sperm directly into the cytoplasm of an oocyte. Several studies have demonstrated efficacy and short-term safety of ICSI (ASRM, 2008d).

It should be noted that in the United States, the reported risk of multiple gestations after ICSI is 30–35% for twin gestations and 5–10% for triplet or higher-order gestations. Some conditions may carry an increased risk for transmission of genetic abnormalities to offspring via ICSI (ASRM, 2008c). Whether the increased prevalence is related to the procedure or to the characteristics of couples who require ICSI is unclear. In general, due to the increased risk all couples who undergo ICSI should undergo genetic counseling.

The ICSI process is as follows:

1. Ovarian stimulation and monitoring: This step is similar to the process used in IVF.
2. Sperm extraction: The sperm sample is evaluated and processed to select healthy, viable sperm for fertilization. If there is an absence of sperm, surgical extraction procedures are performed. Microsurgical epididymal sperm aspiration (MESA) is used when sperm are unable to move through the genital tract. In this procedure, sperm are extracted directly from the epididymides. Sperm may also be extracted from the testes in a procedure called testicular sperm aspiration (TESA) or testicular fine needle aspiration (TEFNA). Although studies are few, some authors have proposed an FNA map prior to TESA to determine sperm location and availability of sperm in men with nonobstructive azoospermia considering TESA. (Turek, et al, 1999; Turek et al., 2000; Meng, et al., 2000). However, evidence is insufficient to support whether a map that shows no sperm is truly predictive of TESA failure. Consequently, the role of FNA mapping in the management of nonobstructive azoospermia is limited. Other techniques include: testicular sperm extraction (TESE), microscopic TESE, percutaneous epididymal sperm aspiration (PESA), vasal sperm aspiration, and seminal vesicle sperm aspiration aided by transrectal ultrasonography. Indications for MESA and PESA include: bilateral congenital absence of vas deferentia (CAVD), cystic fibrosis, vasectomy of failed vasectomy reversal, inoperable ejaculatory ducts or distal vasal obstruction, post-inflammatory obstructions (e.g., gonorrhoea), and radical cystoprostatectomy. Indications for TESA, TEFNA and TESE include: nonobstructive azoospermia (e.g., maturation arrest, hypospermatogenesis), obstructive azoospermia, anejaculation, complete terato/necrozoospermia, and complete sperm immobility. Microscopic TESE involves the use of a high magnification microscope for individuals with extremely low sperm production.
3. Egg retrieval: This step is similar to the IVF retrieval process.
4. Micromanipulation and fertilization with ICSI: Cumulus cells are removed from the oocyte, allowing the embryologist and/or physician to view the oocytes' maturity and suitability to undergo ICSI. A single sperm is injected directly into the cytoplasm of a mature egg using a microinjection pipette. This procedure may be repeated with several sperm and oocytes. ICSI can enhance fertilization of sperm which will not bind to or penetrate an egg. Attempts at ICSI may fail due to egg damage, eggs that are difficult to pierce, and fertilized eggs that fail to divide or stop developing.
5. Embryo transfer via IVF, GIFT, or ZIFT: Eggs may be transferred into the uterus or fallopian tube using IVF, GIFT, or ZIFT.

Indications for ICSI related to male factor infertility:

- * very low numbers of motile sperm
- * severe teratospermia (abnormal sperm)
- * problems with sperm binding to and penetrating the egg
- * antisperm antibodies of sufficient quality to prevent fertilization
- * prior or repeated fertilization failure with standard IVF and fertilization methods
- * frozen sperm collected prior to cancer treatment which may be limited in number and quality
- * absence of sperm secondary to blockage or abnormality of the ejaculatory ducts (in this case, TESA or MESA is used)

While ICSI can improve fertilization in couples with male factor infertility ICSI is often used for couples with normal or borderline semen parameters. According to an ASRM practice committee report data does not support routine use of ICSI for non-male factor infertility, for unexplained infertility, for poor-quality oocytes, when there is low oocyte yield, or for advanced maternal age (ASRM, 2020). ICSI may be of benefit for individuals undergoing IVF with preimplantation genetic testing, for in vitro matured oocytes, and for cryopreserved oocytes (ASRM, 2020).

Miscellaneous Issues Associated With ARTs

Ovarian Hyperstimulation Syndrome (OHS): Ovarian hyperstimulation syndrome is a potential complication of controlled ovarian hyperstimulation with gonadotropin medications. It may be classified as mild, moderate or severe. Mild cases are not usually clinically relevant, although severe cases can be life-threatening. Severe cases may be characterized by extreme ovarian enlargement, ascites, elevated serum creatinine, pleural effusions, oliguria, hemoconcentration and thromboembolic phenomena. Identification of high risk patients includes endocrine monitoring and follicular monitoring. The syndrome is triggered by HCG and if there is potential to develop severe OHS, HCG injections are withheld and the cycle may be cancelled; in IVF cycles the embryos may be frozen (Lobo, 2012b). Other measures of preventing OHS such as coasting and administering HCG when endocrine levels decrease; the use of intravenous albumin at oocyte retrieval; and the use of GnRh antagonist protocols are debatable. Once the condition develops, treatment is supportive and includes correction of electrolyte imbalances and maintenance of urine output.

Preimplantation Genetic Diagnosis (PGD): Preimplantation genetic diagnosis is a technique that allows embryos to be tested for genetic disorders prior to implantation and pregnancy. It is a diagnostic procedure that provides an alternative to traditional prenatal genetic diagnosis. The procedure is recommended when embryos may be affected by certain genetic conditions. One or two cells are removed from the embryos by biopsy during IVF procedures and examined for genetic analysis. Embryos with normal biopsy results are available for transfer into the uterus while additional normal embryos may be frozen. Only normal, healthy embryos are transferred into the uterus, reducing the risk of adverse pregnancy outcomes such as birth defects and miscarriages and possible pregnancy termination after prenatal diagnosis. The value of PGD aneuploidy testing as a universal screening test for all IVF patients has yet to be determined (ASRM, 2018).

Elective Single Embryo Transfer (eSET): Multiple gestations are associated with increased risk of complications in both the fetuses and the mother. Growing concern over this increased incidence of multiple pregnancies has led some countries to mandate limitations of the number of embryos used for transfer. Based on a report published by the Centers for Disease Control and Prevention (CDC), the percentages of eSET among all transfers using fresh nondonor eggs or embryos, by age group from 2003 through 2012, has increased for all age groups (CDC, 2012). In the United States, there has never been a formal or regulated restriction on the number of embryos that a particular clinic may place in a woman's uterus. Clinical outcomes of women undergoing eSET with blastocyst or cleavage stage transfer have been investigated. Study results have demonstrated a decrease in multiple gestations and improved cryopreservation rates (Csokmay, et al, 2011), decreased risks of pre-term birth and low birth-weight (Grady, et al., 2012), and improved live-birth rates (Kresowik, et al., 2011). In 2012 the ASRM published a practice committee opinion regarding eSET. Within this publication they note eSET has been advocated as the only effective means of avoiding a multiple pregnancy in IVF cycles and defines eSET as "the transfer of a single embryo at either the cleavage stage or blastocyst stage of development, and that is selected from a large number of embryos." According to the committee opinion the ASRM recommends consideration of eSET for women with a good prognosis which includes the following (ASRM, 2012a):

- age less than 35 years
- more than one top quality embryo available for transfer
- first or second treatment cycle
- previous successful IVF cycle
- recipient of embryos from donated eggs

Elective SET may be an option for women aged 35-40 years if they have top quality blastocyst-stage embryos available for transfer (ASRM, 2012).

Number of Embryos to Use in Transfers: The ASRM has issued updated practice guidelines (ASRM, 2017) on the appropriate number of embryos to transfer in ART practice. The guidelines were revised as an effort to promote singleton gestation and to reduce the number of multiple pregnancies. According to the ASRM guidelines, depending on the women's age and prognosis, the recommended number of embryos to transfer range varies.

The current guidelines are as follows (ASRM, 2017):

- For patients of any age with a favorable diagnosis, transfer of a euploid embryo has the most favorable prognosis and should be limited to one (Favorable prognosis factors include: young age, expectation of one or more high quality embryo for cryopreservation, euploid embryos, and previous live birth following an IVF cycle).
- For patients under the age of 35 who have a favorable prognosis, consideration should be given to transferring a single embryo, regardless of stage.
- For patients between the ages of 35–37 and having a more favorable prognosis, strong consideration should be given for a single-embryo transfer
- For patients between the ages of 38–40 who have a more favorable prognosis, no more than three cleavage-stage embryos should be transferred or no more than two blastocysts. When euploid embryos are available, a single blastocyst embryo should be the norm.
- For patients 41-42 years of age, no more than four cleavage stage embryos or three blastocysts should be transferred. When euploid embryos are available, a single blastocyst embryo should be the norm.
- In each of the above age groups, for patients with a less favorable prognosis, one additional embryo may be transferred according to individual circumstances. The patient must be counseled regarding the risk of multifetal pregnancy
- In women > 43 years of age, there are insufficient data to recommend a limit on the number of embryos to transfer.
- In donor egg cycles, the age of the donor should be used in determining the number of embryos to transfer.
- In frozen embryo transfer cycles, the number of good quality thawed embryos transferred should not exceed the recommended limit on the number of fresh embryos transferred for each age group.

Low Birth-Weight and Multiple Births: The use of assisted reproductive technology has been reported to be a contributor to the rate of low birth-weight in the United States, as it has been associated with a higher rate of multiple births. Multiple gestations are associated with increased risk for preterm delivery, low birth weight and increased perinatal mortality (Alukal and Lamb, 2008). Additionally, evidence suggests that there is a higher rate of low birth-weight among singleton infants conceived with assisted reproductive technology than among naturally conceived singleton infants or among all infants in the general population (CDC, 2009; McDonald, et al., 2009; Schieve, et al., 2002).

Birth Defects: Hansen et al. (2014) reported the results of a systematic review and meta-analysis (n=45 cohort studies) evaluating the risk of increased birth defects in ART and non-ART infants, and further assessed whether the risk differed between single or multiple births. The published results indicate that the risk of birth defects was higher in ART births compared to non-ART births and the risk further increased when limited to major birth defects or to single births; results regarding multiple births were not clear according to the authors. In general, several studies, systematic reviews, and meta analyses have been published evaluating the occurrence of birth defects in children after the use of ART. Currently, the literature is inconsistent in reported outcomes and in defining a clear relationship to the assisted reproductive technology. Criteria to define birth defects vary among countries making the analysis of ART safety data difficult to analyze (Alukal and Lamb, 2008). In addition, maternal factors may be the cause of birth defects rather than factors associated with the ART. While some authors suggest that there is an increased risk of birth defects with ART compared to spontaneous conceptions, it should be noted that other studies have not shown an increased risk of birth defects with either ICSI or standard IVF. As a result, large population-based studies are needed to address the exact etiology. Overall, the underlying biological mechanism by which ART affects adverse development remains unclear and couples considering ART should be informed of all potential risks and benefits.

Cryopreservation: Cryopreservation may be employed as a method to preserve fertility or as part of assisted reproductive technologies. In general, preservation of fertility is considered not medically necessary. When employed as part of assisted reproductive technologies cryopreservation of some reproductive cells/tissue have been proven safe and effective, although some remain under investigation. Cryopreservation, storage and thawing of testicular tissue is considered unproven in the treatment of infertility (ASRM, 2014).

Cryopreservation of sperm and embryos are well-established services and have been proven safe and effective; cryopreservation of mature oocytes is no longer considered investigational. The ASRM published a practice

committee guideline (ASRM, 2013) for mature oocyte cryopreservation. In 2014 the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecological Practice published a Committee Opinion endorsing the ASRM document. Within the guidelines the ASRM notes limited data exists evaluating the effect of duration of storage on oocyte cryopreservation as well as clinical outcomes and that success rates may not be generalizable. Although success rates generally decline with increased maternal age, there are no comparative trials evaluating success of cryopreserved versus fresh oocytes by age. Furthermore, whether or not the incidence of anomalies and developmental abnormalities of children born from cryopreserved oocytes is similar to those born from cryopreserved embryos has not been firmly established. Nevertheless, although the data is very limited, oocyte cryopreservation may be recommended, with appropriate counseling, for couples pursuing IVF with insufficient sperm on the day of retrieval (e.g., severe oligospermia, azospermia) and for individuals undergoing chemotherapy or other gonadotoxic therapies.

Fertility Preservation: When undergoing potentially gonadotoxic therapies embryo, sperm, mature oocyte cryopreservation and ovarian transposition are considered viable options and standard practice for fertility preservation for select individuals (ASRM, 2019; NCCN, 2021; ASCO, 2018).

There is a paucity of evidence in the peer-reviewed literature evaluating the safety of ovarian tissue and testicular tissue cryopreservation procedures and live birth outcomes following such procedures. In December 2019 the ASRM updated guidelines for fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy (ASRM, 2019). According to these guidelines ovarian tissue cryopreservation for prepubertal girls and for those who cannot delay cancer treatment to undergo ovarian stimulation and oocyte retrieval is no longer considered experimental. The ASRM supports that “data on the efficacy, safety, and reproductive outcomes after ovarian tissue cryopreservation are still limited. Given the current body of literature, ovarian tissue cryopreservation should be considered an established medical procedure with limited effectiveness that should be offered to carefully selected patients”. Testicular tissue cryopreservation in prepubertal males is still considered experimental and should be conducted under research protocols when no other options are feasible. Ovarian transposition may be offered to women undergoing pelvic radiation.

In 2021 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for “Adolescent and Young Adult Oncology” (NCCN, 2021) provide the following guidance with regards to cryopreservation of ovarian tissue for females “Ovarian tissue cryopreservation is a promising strategy for female fertility preservation when there is insufficient time for oocyte or embryo cryopreservation and/or the patient is prepubertal. This technique does not require hormonal stimulation, so there is no long delay in initiation of treatment. It is not considered appropriate for certain women with cancer if there exists a potential for reintroduction of malignant cells with grafting. It is also not recommended for carriers of BRCA mutations due to the increased risk of ovarian cancer. It is recommended transplantation be performed with the purpose of regaining fertility and not gonadal endocrine function. While ovarian tissue cryopreservation is still considered investigational at some institutions, it may be discussed as an option for fertility preservation, if available. For males, cryopreservation and subsequent transplantation of spermatogonial stem cells may be an option for prepubertal males and pubertal males in whom semen cryopreservation is not possible. For males with hematologic or testicular malignancies, autologous transplantation of cryopreserved testicular tissue may not be appropriate for fear of reintroduction of tumor cells. However, immature testicular tissue cryopreservation is still considered experimental. Semen cryopreservation is the most reliable and well established means of preserving fertility for male adolescent and young adult cancers (NCCN; 2021).

2018 American Society of Clinical Oncology (ASCO) clinical practice guidelines for fertility preservation in patients with cancer recommends sperm cryopreservation for postpubertal males receiving gonadotoxic cancer therapies for adult men. Other methods, such as testicular tissue cryopreservation and reimplantation or grafting of human testicular tissue, should be performed only as part of clinical trials or approved experimental protocols. For adult females embryo cryopreservation is considered an option, unfertilized oocyte cryopreservation is no longer experimental, and ovarian tissue cryopreservation for the purpose of future transplantation does not require ovarian stimulation and can be performed immediately. In addition, it does not require sexual maturity and hence may be the only method available in children. Finally, this method may also restore global ovarian function. However, it should be noted further investigation is needed to confirm whether it is safe in patients with leukemias (Oktay, et al., 2018).

Fertility preservation is not recommended for the following circumstances (ASRM, 2013; ACOG 2013):

- oocyte cryopreservation in donor populations/donor banking
- oocyte cryopreservation performed solely to defer childbearing
- oocyte cryopreservation routinely used in lieu of embryo cryopreservation.

The American Board of Internal Medicine’s (ABIM) Foundation Choosing Wisely® Initiative (2014): The ASRM does not recommend performance of any of the following as part of the evaluation of infertility:

- routine diagnostic laparoscopy for the evaluation of unexplained infertility
- advanced sperm function testing, such as sperm penetration or hemizona assays, in the initial evaluation of the infertile couple
- postcoital test (PCT) for the evaluation of infertility.
- routinely order thrombophilia testing on patients undergoing a routine infertility evaluation.
- immunological testing as part of the routine infertility evaluation.

Use Outside of the US: Various guidelines and recommendations are available from organizations outside the U.S. For example, the Australian Government National Health and Medical Research Council, the Society of Obstetricians and Gynaecologists of Canada, and the National Institute for Health and Care Excellence (NICE) (United Kingdom) have published guidelines for infertility related testing and treatment. In addition, regulation of assisted reproductive technologies outside the U.S. varies. For example, the European Commission indicates that reproductive techniques such as IVF are regulated by the Member States and similar to the U.S. organizations, the European Society of Human Reproduction and Embryology collects and periodically reports data from existing registries regarding the use of ART.

Medicare Coverage Determinations

	Contractor	Policy Name/Number	Revision Effective Date
NCD	National	No NCD	
LCD		No LCD	

Note: Please review the current Medicare Policy for the most up-to-date information.

Coding/Billing Information

- Note:** 1) This list of codes may not be all-inclusive.
 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

Diagnostic Testing

Considered Medically Necessary under core medical benefits when criteria in the applicable policy statements listed above are met to establish the etiology of infertility:

CPT®* Codes	Description
49320	Laparoscopy, abdomen, peritoneum, and omentum, diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)
54500	Biopsy of testis, needle (separate procedure)
54505	Biopsy of testis, incisional (separate procedure)
55110	Scrotal exploration
55870	Electroejaculation
58100	Endometrial sampling (biopsy) with or without endocervical sampling (biopsy), without cervical dilation, any method (separate procedure)
58340†	Catheterization and introduction of saline or contrast material for saline infusion sonohysterography (SIS) or hysterosalpingography

CPT®* Codes	Description
58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography
58350	Chromotubation of oviduct, including materials
58555	Hysteroscopy, diagnostic (separate procedure)
74440	Vasography, vesiculography, or epididymography, radiological supervision and interpretation
74740†	Hysterosalpingography, radiological supervision and interpretation
74742	Transcervical catheterization of fallopian tube, radiological supervision and interpretation
76830	Ultrasound, transvaginal
76831†	Saline infusion sonohysterosonography (SIS), including color flow Doppler, when performed
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete
76870	Ultrasound, scrotum and contents
76872	Ultrasound, transrectal
81015	Urinalysis; microscopic only
82670	Estradiol; total
82671	Estrogens; fractionated
82672	Estrogens; total
82679	Estrone
82757	Fructose, semen
83001	Gonadotropin; follicle stimulating hormone (FSH)
83002	Gonadotropin; luteinizing hormone (LH)
84144	Progesterone
84146	Prolactin
84402	Testosterone; free
84403	Testosterone; total
84410	Testosterone; bioavailable, direct measurement (eg, differential precipitation)
84443	Thyroid stimulating hormone (TSH)
84830††	Ovulation tests, by visual color comparison methods for human luteinizing hormone
88280	Chromosome analysis; additional karyotypes, each study
89257	Sperm identification from aspiration (other than seminal fluid)
89260	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis
89261	Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
89264	Sperm identification from testis tissue, fresh or cryopreserved
89300	Semen analysis; presence and/or motility of sperm including Huhner test (post coital)
89310	Semen analysis; motility and count (not including Huhner test)
89320	Semen analysis; volume, count, motility, and differential
89321	Semen analysis; sperm presence and motility of sperm, if performed
89322	Semen analysis; volume, count, motility, and differential using strict morphologic criteria (eg, Kruger)
89325	Sperm antibodies
89330	Sperm evaluation; cervical mucus penetration test, with or without spinnbarkeit test
89331	Sperm evaluation, for retrograde ejaculation, urine (sperm concentration, motility, and morphology, as indicated)

† **Note:** Considered Experimental/Investigational/Unproven when used to report saline-air infused sono-hysterosalpingogram (e.g., femVue® [Femasys, Inc.]).

††**Note:** Considered Not Medically Necessary when used to report home ovulation prediction test kits.

HCPCS Codes	Description
G0027	Semen analysis; presence and/or motility of sperm excluding Huhner
S3655	Antisperm antibodies test (immunobead)

Considered Medically Necessary when used to report Anti-Mullerian hormone testing:

CPT®*	Description
83516	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; qualitative or semiquantitative, multiple step method
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified

Treatment of Infertility

Considered Medically Necessary when criteria in the applicable policy statements listed above are met if benefits are available for infertility treatment:

CPT® *	Description
10004 ^{†††}	Fine needle aspiration biopsy, without imaging guidance; each additional lesion (List separately in addition to code for primary procedure)
10005 ^{†††}	Fine needle aspiration biopsy, including ultrasound guidance; first lesion
10006 ^{†††}	Fine needle aspiration biopsy, including ultrasound guidance; each additional lesion (List separately in addition to code for primary procedure)
10021 ^{†††}	Fine needle aspiration biopsy; without imaging guidance; first lesion
37241	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)
49321	Laparoscopy, surgical; with biopsy (single or multiple)
52402	Cystourethroscopy with transurethral resection or incision of ejaculatory ducts
54500	Biopsy of testis, needle (separate procedure)
54505	Biopsy of testis, incisional (separate procedure)
54640	Orchiopexy, inguinal or scrotal approach
54650	Orchiopexy, abdominal approach, for intra-abdominal testis (eg, Fowler Stephens)
54800	Biopsy of epididymis, needle
54840	Excision of spermatocele, with or without epididymectomy
54860	Epididymectomy; unilateral
54861	Epididymectomy; bilateral
54900	Epididymovasostomy, anastomosis of epididymis to vas deferens; unilateral
54901	Epididymovasostomy, anastomosis of epididymis to vas deferens; bilateral
55400 ^{††††}	Vasovasostomy, vasovasorrhaphy
55500	Excision of hydrocele of spermatic cord, unilateral (separate procedure)
55530	Excision of varicocele or ligation of spermatic veins for varicocele; (separate procedure)
55535	Excision of varicocele or ligation of spermatic veins for varicocele; abdominal approach
55540	Excision of varicocele or ligation of spermatic veins for varicocele; with hernia repair
55550	Laparoscopy, surgical, with ligation of spermatic veins for varicocele
55870	Electroejaculation
58140	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; abdominal approach

CPT® * Codes	Description
58145	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; vaginal approach
58146	Myomectomy, excision of fibroid tumor(s) of uterus, 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g, abdominal approach
58321	Artificial insemination; intra-cervical
58322	Artificial insemination; intra-uterine
58323	Sperm washing for artificial insemination
58345	Transcervical introduction of fallopian tube catheter for diagnosis and/or re-establishing patency (any method), with or without hysterosalpingography
58545	Laparoscopy, surgical, myomectomy, excision; 1 to 4 intramural myomas with total weight of 250 g or less and/or removal of surface myomas
58546	Laparoscopy, surgical, myomectomy, excision; 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g
58558	Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or polypectomy, with or without D & C
58559	Hysteroscopy, surgical; with lysis of intrauterine adhesions (any method)
58560	Hysteroscopy, surgical; with division or resection of intrauterine septum (any method)
58561	Hysteroscopy, surgical; with removal of leiomyomata
58660	Laparoscopy, surgical; with lysis of adhesions (salpingolysis, ovariolysis) (separate procedure)
58662	Laparoscopy, surgical; with fulguration or excision of lesions of the ovary, pelvic viscera, or peritoneal surface by any method
58670	Laparoscopy, surgical; with fulguration of oviducts (with or without transection)
58672	Laparoscopy, surgical; with fimbrioplasty
58673	Laparoscopy, surgical; with salpingostomy (salpingoneostomy)
58700	Salpingectomy, complete or partial, unilateral or bilateral (separate procedure)
58740	Lysis of adhesions (salpingolysis, ovariolysis)
58752	Tubouterine implantation
58760	Fimbrioplasty
58770	Salpingostomy (salpingoneostomy)
58800	Drainage of ovarian cyst(s), unilateral or bilateral (separate procedure); vaginal approach
58805	Drainage of ovarian cyst(s), unilateral or bilateral (separate procedure); abdominal approach
58920	Wedge resection or bisection of ovary, unilateral or bilateral
58925	Ovarian cystectomy, unilateral or bilateral
58970	Follicle puncture for oocyte retrieval, any method
58974	Embryo transfer, intrauterine
58976	Gamete, zygote, or embryo intrafallopian transfer, any method
74440	Vasography, vesiculography, or epididymography, radiological supervision and interpretation
74742	Transcervical catheterization of fallopian tube, radiological supervision and interpretation
76830	Ultrasound, transvaginal
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete
76857	Ultrasound, pelvic (nonobstetric), real time with image documentation; limited or follow-up (eg, for follicles)
76948	Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation
82670	Estradiol, total
83001	Gonadotropin; follicle stimulating hormone (FSH)
83002	Gonadotropin; luteinizing hormone (LH)
84144	Progesterone
84830	Ovulation tests, by visual color comparison methods for human luteinizing hormone
89250	Culture of oocyte(s)/embryo(s), less than 4 days
89253	Assisted embryo hatching, microtechniques (any method)
89254	Oocyte identification from follicular fluid
89255	Preparation of embryo for transfer (any method)

CPT® * Codes	Description
89257	Sperm identification from aspiration (other than seminal fluid)
89260	Sperm isolation; simple prep (eg, sperm wash and swim-up) for insemination or diagnosis with semen analysis
89261	Sperm isolation; complex prep (eg, Percoll gradient, albumin gradient) for insemination or diagnosis with semen analysis
89264	Sperm identification from testis tissue, fresh or cryopreserved
89268	Insemination of oocytes
89272	Extended culture of oocyte(s)/embryo(s), 4-7 days
89280	Assisted oocyte fertilization, microtechnique; less than or equal to 10 oocytes
89281	Assisted oocyte fertilization, microtechnique; greater than 10 oocytes
89290	Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-implantation genetic diagnosis); less than or equal to 5 embryos
89291	Biopsy, oocyte polar body or embryo blastomere, microtechnique (for pre-implantation genetic diagnosis); greater than 5 embryos

††**Note:** Considered Experimental/Investigational/Unproven when used to report fine needle aspiration mapping.

†††**Note:** Considered Not Medically Necessary when used to report the reversal of voluntary sterilization.

HCPCS Codes	Description
S4011	In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
S4013	Complete cycle, gamete intrafallopian transfer (GIFT), case rate
S4014	Complete cycle, zygote intrafallopian transfer (ZIFT), case rate
S4015	Complete in vitro fertilization cycle, not otherwise specified, case rate
S4016	Frozen in vitro fertilization cycle, case rate
S4017	Incomplete cycle, treatment cancelled prior to stimulation, case rate
S4018	Frozen embryo transfer procedure cancelled before transfer, case rate
S4020	In vitro fertilization procedure cancelled before aspiration, case rate
S4021	In vitro fertilization procedure cancelled after aspiration, case rate
S4022	Assisted oocyte fertilization, case rate
S4028	Microsurgical epididymal sperm aspiration (mesa)
S4035	Stimulated intrauterine insemination (IUI), case rate
S4037	Cryopreserved embryo transfer, case rate
S4042	Management of ovulation induction (interpretation of diagnostic tests and studies, non face-to-face medical management of the patient), per cycle

Considered Medically Necessary when used to report sperm extraction methods (e.g., testicular sperm extraction [TESE], micro-dissection testicular sperm extraction [micro-TESE], percutaneous testicular sperm extraction [PESA]) not otherwise coded:

CPT®* Codes	Description
55899	Unlisted procedure, male genital system

Considered Medically Necessary when used to report mock embryo transfer prior to a medically necessary IVF procedure:

CPT®* Codes	Description
58999	Unlisted procedure, female genital system (nonobstetrical)

Cryopreservation Services

State Mandate Coverage

If an applicable state mandate exists for fertility preservation, the following are generally considered medically necessary:

- Cryopreservation, storage and thawing of sperm, oocyte(s) and embryo(s) for individuals facing anticipated infertility resulting from chemotherapy, pelvic radiotherapy, or other procedures expected to render one permanently infertile (Please access the state specific mandate):

CPT®* Codes	Description
89258	Cryopreservation; embryo(s)
89259	Cryopreservation; sperm
89337	Cryopreservation, mature oocyte(s)
89342	Storage (per year); embryo(s)
89343	Storage, (per year); sperm/semen
89346	Storage, (per year); oocyte(s)
89352	Thawing of cryopreserved; embryo(s)
89353	Thawing of cryopreserved; sperm/semen, each aliquot
89356	Thawing of cryopreserved; oocytes, each aliquot

HCPCS Codes	Description
S4027	Storage of previously frozen embryos
S4030	Thawing of cryopreserved; sperm/semen, each aliquot
S4031	Sperm procurement and cryopreservation services; subsequent visit
S4040	Monitoring and storage of cryopreserved embryos, per 30 days

- When used to report re-transplantation of ovarian reproductive tissue and/or cryopreservation of ovarian reproductive tissue (Please access the state specific mandate):

CPT®* Codes	Description
58999	Unlisted procedure, female genital system (nonobstetrical)
89398	Unlisted reproductive medicine laboratory procedure

Considered Experimental/Investigational/Unproven when used to report testicular tissue cryopreservation, testicular tissue re-transplantation, immature oocytes and/or in vitro maturation (Please access the state specific mandate):

CPT®* Codes	Description
55899	Unlisted procedure, male genital system
89335	Cryopreservation, reproductive tissue, testicular
89344	Storage, (per year); reproductive tissue, testicular/ovarian
89354	Thawing of cryopreserved; reproductive tissue, testicular/ovarian
89398	Unlisted reproductive medicine laboratory procedure

Benefit Coverage

Considered Medically Necessary if specific benefit coverage for cryopreservation services are available:

CPT®* Codes	Description
89258	Cryopreservation; embryo(s)
89337	Cryopreservation, mature oocyte(s)
89342	Storage (per year); embryo(s)
89346	Storage, (per year); oocyte(s)
89352	Thawing of cryopreserved; embryo(s)
89356	Thawing of cryopreserved; oocytes, each aliquot

HCPCS Codes	Description
S4027	Storage of previously frozen embryos
S4040	Monitoring and storage of cryopreserved embryos, per 30 days

Considered Not Medically Necessary even if benefit specific coverage for cryopreservation services are available:

CPT®* Codes	Description
89259	Cryopreservation; sperm
89343	Storage, (per year); sperm/semen
89353	Thawing of cryopreserved; sperm/semen, each aliquot

HCPCS Codes	Description
S4030	Sperm procurement and cryopreservation services; initial visit
S4031	Sperm procurement and cryopreservation services; subsequent visit

Considered Experimental/Investigational/Unproven if specific benefit coverage for cryopreservation services are available:

CPT®* Codes	Description
89335	Cryopreservation, reproductive tissue, testicular
89344	Storage, (per year); reproductive tissue, testicular/ovarian
89354	Thawing of cryopreserved; reproductive tissue, testicular/ovarian
0058T	Cryopreservation; reproductive tissue, ovarian (Code deleted 12/31/2020)

Considered Experimental/Investigational/Unproven if specific benefit coverage for cryopreservation services are available AND when used to report re-transplantation of ovarian or testicular reproductive tissue; cryopreservation of ovarian reproductive tissue; immature oocytes and/or in vitro maturation:

CPT®* Codes	Description
55899	Unlisted procedure, male genital system
58999	Unlisted procedure, female genital system (nonobstetrical)
89398	Unlisted reproductive medicine laboratory procedure

Experimental/Investigational/Unproven

Considered Experimental/Investigational/Unproven:

CPT®* Codes	Description
86357	Natural killer (NK) cells, total count
89251	Culture of oocyte(s)/embryo(s), less than 4 days; with co-culture of oocyte(s)/embryos
97810	Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
97811	Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)
97813	Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
97814	Acupuncture, 1 or more needles; with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)
99183	Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session
0664T	Donor hysterectomy (including cold preservation); open, from cadaver donor
0665T	Donor hysterectomy (including cold preservation); open, from living donor
0666T	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor
0667T	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor
0668T	Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of
0669T	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each
0670T	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each

HCPCS Codes	Description
G0277	Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

Considered Experimental/Investigational/Unproven when used to report INVOcell, direct intraperitoneal insemination, intrafollicular insemination, or fallopian tube sperm transfusion:

CPT®* Codes	Description
58999	Unlisted procedure, female genital system (nonobstetrical)

Considered Experimental/Investigational/Unproven when used to report immunological testing:

CPT®* Codes	Description
83519	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA)
86148	Anti-phosphatidylserine (phospholipid) antibody
86360	T-cells; absolute CD4 and CD8 count, including ratio

Considered Experimental/Investigational/Unproven when used to report antiprothrombin (phospholipid cofactor) antibody or embryotoxicity assay:

CPT®* Codes	Description
86849	Unlisted immunology procedure

Considered Experimental/Investigational/Unproven when used to report reproductive immune-phenotype (RIP):

CPT®* Codes	Description
88182	Flow cytometry, cell cycle or DNA analysis
88189	Flow cytometry, interpretation, 16 or more markers

Considered Experimental/Investigational/Unproven when used to report computer-assisted sperm motion analysis, hemizona test, Hyaluronan Binding Assay (HBA), sperm viability test, sperm precursors, laser assisted necrotic blastomere removal from cryopreserved embryos, time-lapse monitoring/storage of embryos:

CPT®* Codes	Description
89398	Unlisted reproductive medicine laboratory procedure

Considered Experimental/Investigational/Unproven when used to report endometrial receptivity testing:

CPT®* Codes	Description
88305	Level IV - Surgical pathology, gross and microscopic examination
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure

Considered Experimental/Investigational/Unproven when used to report fine needle aspiration mapping:

CPT®* Codes	Description
88173	Cytopathology, evaluation of fine needle aspirate; interpretation and report
88106	Cytopathology, fluids, washings or brushings, except cervical or vaginal; simple filter method with interpretation
88108	Cytopathology, concentration technique, smears and interpretation (eg, Saccomanno technique)
88305	Level IV - Surgical pathology, gross and microscopic examination

Considered Experimental/Investigational/Unproven when used to report serum inhibin B:

CPT®* Codes	Description
83520	Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified

Considered Experimental/Investigational/Unproven when used to report manual soft tissue therapy for the treatment of pelvic adhesions (WURN Technique®, Clear Passage Therapy):

CPT®* Codes	Description
97140	Manual therapy techniques (eg, mobilization/manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes

Considered Experimental/Investigational/Unproven when used to report reactive oxygen species testing (ROS):

CPT®* Codes	Description
82397	Chemiluminescent assay

Considered Experimental/Investigational/Unproven when used to report vaginal microbiome testing:

CPT®* Codes	Description
87999	Unlisted microbiology procedure
88199	Unlisted cytopathology procedure

Considered Experimental/Investigational/Unproven when used to report saline-air infused sono-hysterosalpingogram (e.g., femVue® [Femasys, Inc.]):

CPT®* Codes	Description
76999	Unlisted ultrasound procedure (eg, diagnostic, interventional)
0568T	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound

Considered Experimental/Investigational/Unproven when used to report sperm capacitation assay function (e.g., Cap-Score™):

CPT®* Codes	Description
0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score

Considered Not Medically Necessary

Considered Not Medically Necessary even if benefits are available for infertility treatment:

CPT®* Codes	Description
58750	Tubotubal anastomosis
81025	Urine pregnancy test, by visual color comparison methods
89259	Cryopreservation; sperm
89343	Storage, (per year); sperm/semen
89353	Thawing of cryopreserved; sperm/semen, each aliquot

HCPCS Codes	Description
S4023	Donor egg cycle, incomplete, case rate

HCPCS Codes	Description
S4025	Donor services for in vitro fertilization (sperm or embryo), case rate
S4026	Procurement of donor sperm from sperm bank
S4030	Sperm procurement and cryopreservation services; initial visit
S4031	Sperm procurement and cryopreservation services; subsequent visit

***Current Procedural Terminology (CPT®) ©2020 American Medical Association: Chicago, IL.**

References

1. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. The Cochrane Database of Systematic Reviews 2002. In: The Cochrane Library, Issue 2, 2006. ©2006 The Cochrane Collaboration.
2. Aboulghar MA, Mansour RT. Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures. Hum Reprod Update. 2003 May-Jun;9(3):275-89.
3. Adeza Biomedical Corporation. E-tegrity test. Information for physicians. Accessed April 5, 2017. Available at URL address: <http://www.etegritytest.com/>
4. Agarwal A, Allamaneni SS. The effect of sperm DNA damage on assisted reproduction outcomes. A review. Minerva Ginecol. 2004 Jun;56(3):235-45.
5. Agarwal A, Bragais FM, Sabanegh E. Assessing sperm function. Urol Clin North Am. 2008 May;35(2):157-71.
6. Agency for Healthcare Research and Quality. Effectiveness of Assisted Reproductive Technology. Evidence Report/technology Assessment Number 167. May 2008. Accessed April 16, 2021. Available at URL address: <https://archive.ahrq.gov/research/findings/evidence-based-reports/infertil-evidence-report.pdf>
7. Altmäe S, Salumets A. A novel genomic diagnostic tool for sperm quality? Reprod Biomed Online. 2011 Feb 13.
8. Alukal JP, Lamb DJ. Intracytoplasmic Sperm Injection (ICSI) - What are the Risks? Urol Clin North Am. 2008 May;35(2):277-88.
9. American College of Obstetricians and Gynecologists, Sonohysterography. Frequently Asked Questions. (FAQ). © Copyright December 2016 by the American College of Obstetricians and Gynecologists.
10. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Practice Committee of the American Society for Reproductive Medicine. Committee opinion no. 589: female age-related fertility decline. Obstet Gynecol. 2014 Mar;123(3):719-21. Reaffirmed 2020.
11. American College of Obstetricians and Gynecologists (ACOG), ACOG Committee on Obstetric Practice; ACOG Committee on Gynecologic Practice; ACOG Committee on Genetics. ACOG Committee Opinion #324: Perinatal risks associated with assisted reproductive technology. Obstet Gynecol. 2005 Nov;106(5 Pt 1):1143-6. Reaffirmed 2020.
12. ACOG Committee Opinion No. 649: Racial and Ethnic Disparities in Obstetrics and Gynecology. Obstet Gynecol. 2015 Dec;126(6):e130-e134 Reaffirmed 2018.

13. American Society for Reproductive Medicine (ASRM). American Society of Reproductive Medicine position statement on uterus transplantation: a committee opinion. *Fertil Steril* 2018;110:605-10. ©2018 by American Society for Reproductive Medicine.
14. American Society for Reproductive Medicine (ASRM). Mature oocyte cryopreservation: a guideline. *Fertil Steril*. 2013a Jan;99(1):37-43.
15. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Blastocyst culture and transfer in clinical-assisted reproduction. ©2018 American Society for Reproductive Medicine. *Fertil Steril*. Volume 110. No 7, December 2018.
16. American Society for Reproductive Medicine (ASRM). A Practice Committee Technical Bulletin. Correct Coding for Laboratory Procedures During Assisted Reproductive Technology Cycles. *Fertility Steril* 2016. ©2016 American Society for Reproductive Medicine.
17. American Society for Reproductive Medicine (ASRM). A Practice Committee Opinion. Definitions of infertility and recurrent pregnancy loss. ©*Fertil Steril*. 2020;113:533–5. 2019 by American Society for Reproductive Medicine.
18. American Society for Reproductive Medicine (ASRM). A Practice Committee Educational Bulletin. Effectiveness and Treatment for Unexplained Infertility. September 2000, revised June 2006. ©2006 American Society for Reproductive Medicine *Fertil Steril*. 2006 Nov;86(4).
19. American Society for Reproductive Medicine (ASRM). Evidence-based treatments for couples with unexplained infertility: a guideline. *Fertil Steril*. 2020;113:305–22. © 2019 by American Society for Reproductive Medicine. Accessed April 30, 2021. Available at URL address: https://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/practice-guidelines/for-non-members/evidenece-based_treatments_for_couples_with_unexplained_infertility.pdf
20. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Elective single-embryo transfer. *Fertil Steril*. 2012a;97:835-42.
21. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Genetic considerations related to intracytoplasmic sperm injection (ICSI). ©2008 American Society for Reproductive Medicine. *Fertil Steril*. 2008c Nov;90(5 Suppl):S182-4.
22. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Guidelines on Number of Embryos Transferred. August 2013. *Fertility Steril* 2017; 107-901-3. ©2017 American Society for Reproductive Medicine.
23. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Induction of Ovarian Follicle Development and Ovulation with Exogenous Gonadotropins. 1998. ©2000-2003 American Society for Reproductive Medicine.
24. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. Intracytoplasmic sperm injection (ICSI). ©2008 American Society for Reproductive Medicine. *Fertil Steril*. 2008d Nov;90(5 Suppl):S187.
25. American Society for Reproductive Medicine (ASRM). A Committee Opinion. Intracytoplasmic sperm injection (ICSI) for non-male factor infertility. *Fertil Steril*. 2020;114:239–45. ©2020 by American Society for Reproductive Medicine.
26. American Society for Reproductive Medicine (ASRM). A Practice Committee Opinion. Multiple gestation associated with infertility therapy. 2012c. (replaces 2006 ASRM document). ©2006 American Society for Reproductive Medicine.

27. American Society for Reproductive Medicine (ASRM). Diagnostic evaluation of the infertile female: a committee opinion. *Fertil Steril* 2015; 103:e44-50. © 2015 American Society for Reproductive Medicine.
28. American Society for Reproductive Medicine (ASRM). Diagnostic evaluation of the infertile male: a committee opinion. *Fertil Steril* 2015; © 2015 American Society for Reproductive Medicine.
29. American Society for Reproductive Medicine (ASRM). A Practice Committee Technical Bulletin. Sperm retrieval for obstructive azoospermia. *Fertil Steril*. 2008e Nov;90(5 Suppl):S213-8.
30. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. The Role of Assisted Hatching in in vitro fertilization: a guideline. *Fertil Steril* 2014; 102-348-51. © 2014 American Society for Reproductive Medicine.
31. American Society for Reproductive Medicine (ASRM). A Practice Committee Report. The Clinical Utility of Sperm DNA Integrity Testing. ©2008 American Society for Reproductive Medicine. *Fertil Steril*. 2008g Nov;90(5 Suppl):S178-80.
32. American Society for Reproductive Medicine (ASRM). The Clinical Utility of Sperm DNA Integrity Testing: A guideline. The Practice Committee of the ASRM. *Fertil Steril* 99:3; March 2013, p 673-677.
33. American Society of Reproductive Medicine (ASRM). In vitro maturation: a committee opinion. *Fertil Steril*. 2021;115:298-304. ©2020 American Society for Reproductive Medicine.
34. American Society for Reproductive Medicine (ASRM). Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. *Fertil Steril* 2016; 106-1634-47. © 2016 American updated Society for Reproductive Medicine.
35. American Society for Reproductive Medicine (ASRM). The management of obstructive azoospermia: a committee opinion. *Fertil Steril* 2019; 111:873-80. © 2019 American Society for Reproductive Medicine.
36. American Society of Reproductive Medicine (ASRM). Current clinical irrelevance of luteal phase deficiency: a committee opinion. *Fertil Steril* 2015;103:e27-e32. Accessed April 23, 2020. Available at URL address: <https://www.asrm.org/special-pages/search-results/?q=luteal+phase>
37. American Society of Reproductive Medicine (ASRM) Diagnostic evaluation of the infertile male: A committee opinion. *Fertil Steril* 2015;103:e18-e25. Accessed April 23, 2020. Available at URL address: <https://www.asrm.org/special-pages/search-results/?q=infertile+male>
38. American Society for Reproductive Medicine (ASRM). Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline. © 2020 by the American Urological Association and American Society for Reproductive Medicine. Accessed April 30, 2021. Available at URL address: <https://www.asrm.org/news-and-publications/practice-committee-documents/>
39. American Society for Reproductive Medicine (ASRM). Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline part I. © 2020 by the American Urological Association and American Society for Reproductive Medicine. Accessed April 30, 2021. Available at URL address: <https://www.asrm.org/news-and-publications/practice-committee-documents/>
40. American Society for Reproductive Medicine (ASRM). Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline part II. © 2020 by the American Urological Association and American Society for Reproductive Medicine. Accessed April 30, 2021. Available at URL address: <https://www.asrm.org/news-and-publications/practice-committee-documents/>
41. American Society of Reproductive Medicine (ASRM). Evidence based treatments for couples with unexplained infertility: a guideline. *Fertil Steril*. 2020;113-305-22. © 2020 American Society for Reproductive Medicine.

42. American Society of Reproductive Medicine (ASRM). Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. *Fertil Steril*. 2019; Vol 12, No. 6, 1022-33. © 2019 American Society for Reproductive Medicine.
43. American Society of Reproductive Medicine (ASRM). Use of preimplantation genetic testing: a committee opinion. *Fertil Steril* 2018; 109:429-36. © 2018 by American Society for Reproductive Medicine.
44. American Society for Reproductive Medicine (ASRM). Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertil Steril*. 2020;114:1151-7. ©2020 by American Society for Reproductive Medicine.
45. American Society for Reproductive Medicine (ASRM). Testing and interpreting measures of ovarian reserve: a committee opinion. *Fertil Steril*. 2020;114:1151-7. ©2020 by American Society for Reproductive Medicine.
46. American Urological Association, Inc. (AUA) The Optimal Evaluation of the Infertile Male. AUA Best Practice Statement. Published April 2001. Revised 2011 (a). Accessed April 23, 2020. Available at URL address: <https://www.auanet.org/guidelines/male-infertility-optimal-evaluation-best-practice-statement>
47. American Urological Association, Inc (AUA). Report on Evaluation of the Azoospermic Male. An AUA Best Practice Policy and ASRM Practice Committee Report. Published April 2001. Revised 2011(b). Accessed April 23, 2020. Available at URL address: <https://www.auanet.org/guidelines/azoospermic-male-best-practice-statement>
48. Amorim CA, Leonel ECR, Afifi Y, Coomarasamy A, Fishel S. Cryostorage and retransplantation of ovarian tissue as an infertility treatment. *Best Pract Res Clin Endocrinol Metab*. 2019 Feb;33(1):89-102.
49. Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC. The value of anti-Mullerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. *Hum Reprod*. 2012 Jun;27(6):1829-39.
50. Baruffi RL, Mauri AL, Petersen CG, Nicoletti A, Pontes A, Oliveira JB, Franco JG Jr. Single-embryo transfer reduces clinical pregnancy rates and live births in fresh IVF and Intracytoplasmic Sperm Injection (ICSI) cycles: a meta-analysis. *Reprod Biol Endocrinol*. 2009 Apr 23;7:36.
51. Bellver J, Muñoz EA, Ballesteros A, Soares SR, Bosch E, Simón C, Pellicer A, Remohí J. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study. *Hum Reprod*. 2003 Nov;18(11):2283-8.
52. Benchaib M, Braun V, Lornage J, Hadj S, Salle B, Lejeune H, Guerin JF. Sperm DNA fragmentation decreases the pregnancy rate in an assisted reproductive technique. *Hum Reprod*. 2003 May;18(5):1023-8.
53. Benchaib M, Lornage J, Mazoyer C, Lejeune H, Salle B, Francois Guerin J. Sperm deoxyribonucleic acid fragmentation as a prognostic indicator of assisted reproductive technology outcome. *Fertil Steril*. 2007 Jan;87(1):93-100. Epub 2006 Oct 30.
54. Blake D, Proctor M, Johnson N, Olive D. Cleavage stage versus blastocyst stage embryo transfer in assisted conception. *The Cochrane Database of Systematic Reviews* 2005. . In: *The Cochrane Library*, Issue 2, 2008. ©2008 The Cochrane Collaboration.
55. Boomsma CM, Keay SD, Macklon NS. Peri-implantation glucocorticoid administration for assisted reproductive technology cycles. *Cochrane Database Syst Rev*. 2007. In: *The Cochrane Library*, Issue 2, 2008. ©2008 The Cochrane Collaboration.
56. Bourgain C, Devroey P. The endometrium in stimulated cycles for IVF. *Hum Reprod Update*. 2003 Nov-Dec;9(6):515-22.

57. Bracewell-Milnes T, Saso S, Abdalla H, et al. Metabolomics as a tool to identify biomarkers to predict and improve outcomes in reproductive medicine: a systematic review. *Hum Reprod Update*. 2017 Nov 1;23(6):723-736 (abstract only).
58. Bradshaw KD, Chantilis SJ, Carr BR. Diagnostic Evaluation and Treatment Algorithms for the Infertile Couple. In: Carr, BR, Blackwell RE, editors. *Textbook of Reproductive Medicine*. Stamford CT: Appleton & Lange; 1998. pp.533-47.
59. Brännström M, Johannesson L, Dahm-Kähler P, Enskog A, Mölne J, Kvarnström N, et al. First clinical uterus transplantation trial: a six-month report. *Fertil Steril*. 2014 May;101(5):1228-36.
60. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. *J Clin Endocrinol Metab*. 2013 Mar;98(3):1107-14.
61. Broer SL, Mol B, Dölleman M, Fauser BC, Broekmans FJ. The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. *Curr Opin Obstet Gynecol*. 2010 Jun;22(3):193-201.
62. Brown DB1, Merryman DC, Rivnay B, Houserman VL, Long CA, Honea KL. Evaluating a novel panel of sperm function tests for utility in predicting intracytoplasmic sperm injection (ICSI) outcome. *J Assist Reprod Genet*. 2013 Apr;30(4):461-77.
63. Brucker SY, Strowitzki T, Taran FA, et al. Living-Donor Uterus Transplantation: Pre-, Intra-, and Postoperative Parameters Relevant to Surgical Success, Pregnancy, and Obstetrics with Live Births. *J Clin Med*. 2020 Aug 3;9(8):2485.
64. Brugh VM 3rd, Matschke HM, Lipshultz LI. Male factor infertility. *Endocrinol Metab Clin North Am*. 2003 Sep;32(3):689-707.
65. Bukman A, Heineman MJ. Ovarian reserve testing and the use of prognostic models in patients with subfertility. *Hum Reprod Update*. 2001 Nov-Dec;7(6):581-90.
66. Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. *Fertil Steril*. 2011 Apr 15.
67. Cap-Score™. Cap-score assay. Androvia LifeSciences. Accessed August 22, 2021. <https://www.androviaifesciences.com/>
68. Castellón LAR, Amador MIG, González RED, Eduardo MSJ, Díaz-García C, Kvarnström N, Brännström M. The history behind successful uterine transplantation in humans. Send to
 - a. *JBRA Assist Reprod*. 2017 Jun 1;21(2):126-134.
69. Cedars M, Evans W, Santor N. Premature ovarian failure. *J Clin Endocrinol Metab*. 2008 Feb;93(2);i.
70. Centers for Disease Control and Prevention. Reproductive Health Information Source. 2016 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Accessed April 16, 2021. Available at URL address: <https://www.cdc.gov/art/reports/2016/fertility-clinic.html>
71. Centers for Disease Control and Prevention. Reproductive Health Information Source. 2017 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Accessed April 16, 2021. Available at URL address: <https://www.cdc.gov/art/reports/2016/fertility-clinic.html>
72. Centers for Disease Control and Prevention. Reproductive Health Information Source. 2018 Assisted Reproductive Technology Fertility Clinic Success Rates Report. Accessed April 16, 2021. Available at URL address: <https://www.cdc.gov/art/artdata/index.html>

73. Charehjooy N, Najafi MH, Tavalae M, Deemeh MR, Azadi L, Shiravi AH, Nasr-Esfahani MH. Selection of Sperm Based on Hypo-Osmotic Swelling May Improve ICSI Outcome: A Preliminary Prospective Clinical Trial. *Int J Fertil Steril*. 2014 Apr;8(1):21-8.
74. Combelles CMH, Chateau G. The use of immature oocytes in the fertility preservation of cancer patients: current promises and challenges. *Int. J. Dev. Biol*. 2012; 56: 919-929.
75. Csokmay JM, Hill MJ, Chason RJ, Hennessy S, James AN, Cohen J, Decherney AH, Segars JH, Payson MD. Experience with a patient-friendly, mandatory, single-blastocyst transfer policy: the power of one. *Fertil Steril*. 2011 Sep;96(3):580-4.
76. Daolio J, Palomba S, Paganelli S, Falbo A, Aguzzoli L. Uterine transplantation and IVF for congenital or acquired uterine factor infertility: A systematic review of safety and efficacy outcomes in the first 52 recipients. *PLoS One*. 2020 Apr 29;15(4):e0232323.
77. Desai N, Ploskonka S, Goodman LR, Austin C, Goldberg J, Falcone T. Analysis of embryo morphokinetics, multinucleation and cleavage anomalies using continuous time-lapse monitoring in blastocyst transfer cycles. *Reprod Biol Endocrinol*. 2014 Jun 20;12:54.
78. Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C. A genomic diagnostic tool for human endometrial receptivity based on the transcriptomic signature. *Fertil Steril*. 2011 Jan;95(1):50-60, 60.e1-15.
79. Dicky RP. The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society for Assisted Reproductive Technology/American Society for Reproductive Medicine recommendation to limit the number of embryos transferred. *Fertil Steril*. 2007 May.
80. Dieke AC, Zhang Y, Kissin DM, Barfield WD, Boulet SL. Disparities in Assisted Reproductive Technology Utilization by Race and Ethnicity, United States, 2014: A Commentary. *J Womens Health (Larchmt)*. 2017 Jun;26(6):605-608.
81. Donnez J, Dolmans MM. Fertility Preservation in Women. *N Engl J Med*. 2017 Oct 26;377(17):1657-1665.
82. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, Ernst E, Luyckx V, Andersen CY. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. *Fertil Steril*. 2013 May;99(6):1503-13.
83. Doody KJ, Broome EJ, Doody KM. Comparing blastocyst quality and live birth rates of intravaginal culture using INVOcell™ to traditional in vitro incubation in a randomized open-label prospective controlled trial. *J Assist Reprod Genet*. 2016 Apr;33(4):495-500.
84. Dubowy RL, Feinberg RF, Keefe DL, Doncel GF, Williams SC, McSweet JC, Kliman HJ. Improved endometrial assessment using cyclin E and p27. *Fertil Steril*. 2003 Jul;80(1):146-56.
85. Esteves SC, Agarwal A. Novel concepts in male infertility. *Int Braz J Urol*. 2011 Jan-Feb;37(1):5-15.
86. Ethics Committee of the American Society for Reproductive Medicine (ASRM). Electronic address: asrm@asrm.org. Disparities in access to effective treatment for infertility in the United States: an Ethics Committee opinion. *Fertil Steril*. 2021 Jul;116(1):54-63.
87. Femasys, Inc. femVue® Saline Air Device. Accessed April 23, 2020. Available at URL address: <http://www.femvue.com/>

88. Gabrielsen A, Agerholm I, Toft B, Hald F, Petersen K, Aagaard J, Feldinger B, Lindenberg S, Fedder J. Assisted hatching improves implantation rates on cryopreserved-thawed embryos. A randomized prospective study. *Hum Reprod.* 2004 Oct;19(10):2258-62.
89. Gangel EK. Practice Guidelines. AUA and ASRM Produce Recommendations for Male Infertility. *Am Fam Phys* 2002 Jun 15;65(12):2589-90.
90. Gellert SE, Pors SE, Kristensen SG. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. *J Assist Reprod Genet.* 2018 Apr;35(4):561-570.
91. Ghazeeri GS, Kutteh WH. Immunological testing and treatment in reproduction: frequency assessment of practice patterns at assisted reproduction clinics in the USA and Australia. *Hum Reprod.* 2001 Oct;16(10):2130-5.
92. Gosden LV, Yin H. Micromanipulation in assisted reproductive technology: Intracytoplasmic sperm injection, assisted hatching, and preimplantation genetic diagnosis. *Clin Obstet Gynecol.* 2006 Mar;49(1):73-84.
93. Grady R, Alavi N, Vale R, Khandwala M, McDonald SD. Elective single embryo transfer and perinatal outcomes: a systematic review and meta-analysis. *Fertil Steril.* 2012 Feb;97(2):324-31.
94. Guerif F, Lemseffer M, Couet ML, Gervereau O, Ract V, Royère D. Serum antimüllerian hormone is not predictive of oocyte quality in vitro fertilization. *Ann Endocrinol (Paris).* 2009 Sep;70(4):230-4.
95. Hansen M, Kurinczuk JJ, Bower C, Webb S. The risk of major birth defects after intracytoplasmic sperm injection and in vitro fertilization. *N Engl J Med.* 2002 Mar;346(10):725-30.
96. Hansen M1, Kurinczuk JJ, Milne E, de Klerk N, Bower C. Assisted reproductive technology and birth defects: a systematic review and meta-analysis. *Hum Reprod Update.* 2013 Jul-Aug;19(4):330-53.
97. Hansen M, Bower C, Milne E, de Klerk N, Kurinczuk JJ. Assisted reproductive technologies and the risk of birth defects--a systematic review. *Hum Reprod.* 2005 Feb;20(2):328-38.
98. Hayes, Inc. Ovarian Tissue Cryopreservation for Preservation of fertility in Adult Women Undergoing Gonadotoxic Cancer Treatment. *Health Technology Brief.* © 2017 Winifred S. Hayes, Inc. Dec, 2016, Annual review Nov 2017.
99. Harris SE, Sandlow JI. Sperm acquisition in nonobstructive azoospermia: What are the options? *Urol Clin N Am.* 2008 May;35(2):235-42.
100. Hill MJ, Levens ED. Is there a benefit in follicular flushing in assisted reproductive technology? *Curr Opin Obstet Gynecol.* 2010 Jun;22(3):208-12.
101. Huszar G, Ozenci CC, Cayli S, Zavaczki Z, Hansch E, Vigue L. Hyaluronic acid binding by human sperm indicates cellular maturity, viability, and unreacted acrosomal status. *Fertil Steril.* 2003 Jun;79 Suppl 3:1616-24.
102. INVO Bioscience. INVOcell™. Accessed May 7, 2019. Available at URL address: <https://invobioscience.com/resources/>
103. Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. *Fertil Steril.* 2007 Oct;88(4):982-5.

104. Jain T, Missmer SA, Hornstein MD. Trends in embryo-transfer practice and in outcomes of the use of assisted reproductive technology in the United States. *N Engl J Med*. 2004 Apr 15;350(16):1639-45.
105. Jefferys A, Siassakos D, Wardle P. The management of retrograde ejaculation: a systematic review and update. *Fertil Steril*. 2012 Feb;97(2):306-12.
106. Johannesson L, Järholm S. Uterus transplantation: current progress and future prospects. *Int J Womens Health*. 2016 Feb 5;8:43-51.
107. Johannesson L, Kvarnström N, Mölne J, Dahm-Kähler P, Enskog A, Diaz-Garcia C, Olausson M, Brännström M. Uterus transplantation trial: 1-year outcome. *Fertil Steril*. 2015 Jan;103(1):199-204.
108. Johnson N, Vandekerckhove P, Watson A, Lilford R, Harada T, Hughes E. Tubal flushing for subfertility. *The Cochrane Database of Systematic Reviews* 2005. In: *The Cochrane Library*, 2008 Issue 2, ©2008 The Cochrane Collaboration.
109. Kang SM, Lee SW, Jeong HJ, Yoon SH, Lim JH, Lee SG. Comparison of elective single cleavage-embryo transfer to elective single blastocyst-embryo transfer in human IVF-ET. *Clin Exp Reprod Med*. 2011 Mar;38(1):53-60.
110. Kaya C, Pabuccu R, Satioglu H. Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction. *Fertil Steril*. 2010 Nov;94(6):2202-7.
111. Kervancioglu ME, Saridogan E, Atasu T, Camlibel T, Demircan A, Sarikamis B, Djahanbakhch O. Human Fallopian tube epithelial cell co-culture increases fertilization rates in male factor infertility but not in tubal or unexplained infertility. *Hum Reprod*. 1997 Jun;12(6):1253-8.
112. Khera M, Lipshultz LI. Evolving approach to the varicocele. *Urol Clin N Am*. 2008 May;35(2):183-189.
113. Kini S, Li HW, Morrell D, Pickering S, Thong KJ. Anti-müllerian hormone and cumulative pregnancy outcome in in-vitro fertilization. *J Assist Reprod Genet*. 2010 Aug;27(8):449-56.
114. Kissin DM, Kulkarni AD, Kushnir VA, Jamieson DJ; National ART Surveillance System Group. Number of embryos transferred after in vitro fertilization and good perinatal outcome. *Obstet Gynecol*. 2014 Feb;123(2 Pt 1):239-47.
115. Kliman HJ, Honig S, Walls D, Luna M, McSweet JC, Copperman AB. Optimization of endometrial preparation results in a normal endometrial function test (EFT) and good reproductive outcome in donor ovum recipients. *J Assist Reprod Genet*. 2006 Jul-Aug;23(7-8):299-303.
116. Kolettis PN. Evaluation of the subfertile man. *Am Fam Physician*. 2003 May 15;67(10):2165-72.
117. Kresowik JD, Stegmann BJ, Sparks AE, Ryan GL, van Voorhis BJ. Five-years of a mandatory single-embryo transfer (mSET) policy dramatically reduces twinning rate without lowering pregnancy rates. *Fertil Steril*. 2011 Dec;96(6):1367-9.
118. Kruger TF, Coetsee K. The role of sperm morphology in assisted reproduction. *Hum Reprod Update*. 1999 Mar-Apr;5(2):172-8.
119. Kunt C, Ozaksit G, Keskin Kurt R, Cakir Gungor AN, Kanat-Pektas M, Kilic S, Dede A. Anti-Müllerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization. *Arch Gynecol Obstet*. 2011 Jun;283(6):1415-21.
120. Kwak-Kim J, Gilman-Sachs A. Clinical implication of natural killer cells and reproduction. *Am J Reprod Immunol*. 2008 May;59(5):388-400.

123. Kwak-Kim J, Han AR, Gilman-Sachs A, Fishel S, Leong M, Shoham Z. Current trends of reproductive immunology practices in in vitro fertilization (IVF) - a first world survey using IVF-Worldwide.com. *Am J Reprod Immunol*. 2013 Jan;69(1):12-20.
124. Kwak-Kim JY, Gilman-Sachs A, Kim CE. T helper 1 and 2 immune responses in relationship to pregnancy, nonpregnancy, recurrent spontaneous abortions and infertility of repeated implantation failures. *Chem Immunol Allergy*. 2005;88:64-79.
125. La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, Xella S, Marsella T, Tagliasacchi D, D'Amico R, Volpe A. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. *Reprod Biomed Online*. 2011 Apr;22(4):341-9.
126. Levens ED, Whitcomb BW, Payson MD, Larsen FW. Ovarian follicular flushing among low-responding patients undergoing assisted reproductive technology. *Fertil Steril*. 2009 Apr;91(4 Suppl):1381-4..
127. Liu WX, Luo MJ, Huang P, Wang L, Zhao CY, Yue LM, Zheng Y. Effects of removal of necrotic blastomeres from human cryopreserved embryos on pregnancy outcome. *Cryo Letters*. 2007 Mar-Apr;28(2):129-36.
128. Lobo RA. Endometriosis. In: Lentz: *Comprehensive Gynecology*, 6th ed. CH 19 Endometrioses: Etiology, Pathology Diagnosis, Management. Copyright © 2012 Mosby(a).
129. Lobo RA. Ovarian Hyperstimulation In: Katz: *Comprehensive Gynecology*, 6th ed. CH 41 Infertility: Etiology, Diagnostic Evaluation, Management Prognosis. Copyright © 2012 Mosby(b).
130. Loutradi KE, Prassas I, Bili E, Sanopoulou T, Bontis I, Tarlatzis BC. Evaluation of a transfer medium containing high concentration of hyaluronan in human in vitro fertilization. *Fertil Steril*. 2007 Jan;87(1):48-52. Epub 2006 Oct 30.
131. Lucena E, Saa AM, Navarro DE, Pulido C, Lombana O, Moran A. INVO procedure: minimally invasive IVF as an alternative treatment option for infertile couples. *ScientificWorldJournal*. 2012;2012:571596.
132. Maheux-Lacroix S, Boutin A, Moore L, et al., Hysterosalpingography for diagnosing tubal occlusion in subfertile women: a systematic review with meta-analysis. *Human Reproduction*, 2014;29:5; 953-963.
133. Mathur R, Kailasam C, Jenkins J. Review of the evidence base of strategies to prevent ovarian hyperstimulation syndrome. *Hum Fertil (Camb)*. 2007 Jun;10(2):75-85.
134. McDonald SD, Han Z, Mulla S, Murphy KE, Beyene J, Ohlsson A; Knowledge Synthesis Group. Preterm birth and low birth weight among in vitro fertilization singletons: a systematic review and meta-analyses. *Eur J Obstet Gynecol Reprod Biol*. 2009 Oct;146(2):138-48.
135. McLernon DJ, Harrild K, Bergh C, Davies MJ, de Neubourg D, Dumoulin JC, Gerris J, et al. Clinical effectiveness of elective single versus double embryo transfer: meta-analysis of individual patient data from randomised trials. *BMJ*. 2010 Dec 21;341:c6945. doi: 10.1136/bmj.c6945.
136. Meng MV, Cha I, Ljung BM, Turek PJ. Relationship between classic histological pattern and sperm findings on fine needle aspiration map in infertile men. *Hum Reprod*. 2000 Sep;15(9):1973-7.
137. Miller D, Pavitt S, Sharma V, et al. Physiological, hyaluronan-selected intracytoplasmic sperm injection for infertility treatment (HABSelect): a parallel, two-group, randomised trial. *Lancet*. 2019 Feb 2;393(10170):416-422.
138. Min JK, Hughes E, Young D, Gysler M, Hemmings R, Cheung AP, et al.; Joint Society of Obstetricians and Gynaecologists of Canada-Canadian Fertility and Andrology Society Clinical Practice Guidelines

- Committee. Elective single embryo transfer following in vitro fertilization. *J Obstet Gynaecol Can.* 2010 Apr;32(4):363-77.
139. Mitchell AA. Editorials. Infertility Treatment-More Risks and Challenges. *N Engl J Med.* 2002 Mar 7;346(10):769-70.
140. Mitri F, Esfandiari N, Coogan-Prewer J, Chang P, Bentov Y, McNaught J, Klement AH, Casper RF. A pilot study to evaluate a device for the intravaginal culture of embryos. *Reprod Biomed Online.* 2015 Dec;31(6):732-8.
141. Nagy ZP, Taylor T, Elliott T, Massey JB, Kort HI, Shapiro DB. Removal of lysed blastomeres from frozen-thawed embryos improves implantation and pregnancy rates in frozen embryo transfer cycles. *Fertil Steril.* 2005 Dec;84(6):1606-12.
142. National Comprehensive Cancer Network (NCCN®) Clinical Practice Guidelines in Oncology™. Adolescent and young adult (AYA) oncology. © 2021 National Comprehensive Cancer Network, Inc. V1. 2021 Accessed April 16, 2021. Available at URL address: aya.pdf (nccn.org)
143. Ohl DA, Quallich SA, Sønksen J, Brackett NL, Lynne CM. Anejaculation and retrograde ejaculation. *Urol Clin North Am.* 2008 May;35(2):211-20.
144. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients with Cancer: ASCO Clinical Practice Guideline. Published April 5, 2018. © 2018 by American Society of Clinical Oncology.
145. Omland AK, Fedorcsak P, Storeng R, Dale PO, Abyholm T, Tanbo T. Natural cycle IVF in unexplained, endometriosis-associated and tubal factor infertility. *Hum Reprod.* 2001 Dec;16(12):2587-92.
146. Pan MM, Hockenberry MS, Kirby EW, Lipshultz LI. Male Infertility Diagnosis and Treatment in the Era of In Vitro Fertilization and Intracytoplasmic Sperm Injection. *Med Clin North Am.* 2018 Mar;102(2):337-347.
147. Pandian Z, Bhattacharya S, Ozturk O, Serour G, Templeton A. Number of embryos for transfer following in-vitro fertilisation or intra-cytoplasmic sperm injection. *Cochrane Database Syst Rev.* 2009 Apr 15;(2):CD003416.
148. Pandian Z, Bhattacharya S, Vale L, Templeton A. In vitro fertilisation for unexplained subfertility. *The Cochrane Database of Systematic Reviews* 2005. In: *The Cochrane Library*, 2008, Issue 2, ©2008 The Cochrane Collaboration.
149. Papanikolaou EG, Kolibianakis EM, Tournaye H, Venetis CA, Fatemi H, Tarlatzis B, Devroey P. Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysis. *Hum Reprod.* 2008 Jan;23(1):91-9. Epub 2007 Oct 26.
150. Pregl Breznik B1, Kovačič B, Vlaisavljević V. Are sperm DNA fragmentation, hyperactivation, and hyaluronan-binding ability predictive for fertilization and embryo development in in vitro fertilization and intracytoplasmic sperm injection? *Fertil Steril.* 2013 Apr;99(5):1233-41.
151. Reefhuis J, Honein MA, Schieve LA, Correa A, Hobbs CA, Rasmussen SA; National Birth Defects Prevention Study. Assisted reproductive technology and major structural birth defects in the United States. *Hum Reprod.* 2009 Feb;24(2):360-6.
152. Ricci S, Bennett C, Falcone T. Uterine Transplantation: Evolving Data, Success, and Clinical Importance. *J Minim Invasive Gynecol.* 2021 Mar;28(3):502-512. doi: 10.1016/j.jmig.2020.12.015. Epub 2020 Dec 24.
153. Richlin SS, Shanti A, Murphy AA. Assisted hatching prior to embryo transfer. In: *Danforth's Obstetrics and Gynecology*. Lippincott Williams and Wilkins. © 2003 Lippincott Williams and Wilkins.ch 39.

154. Rienzi L, Nagy ZP, Ubaldi F, Iacobelli M, Anniballo R, Tesarik J, Greco E. Laser-assisted removal of necrotic blastomeres from cryopreserved embryos that were partially damaged. *Fertil Steril*. 2002 Jun;77(6):1196-201.
155. Rienzi L, Ubaldi F, Iacobelli M, Minasi MG, Romano S, Ferrero S, Sapienza F, Baroni E, Tesarik J, Greco E. Developmental potential of fully intact and partially damaged cryopreserved embryos after laser-assisted removal of necrotic blastomeres and post-thaw culture selection. *Fertil Steril*. 2005 Oct;84(4):888-94.
156. Rubio I, Galan A, Larreategui Z, et al. Clinical validation of embryo culture and selection by morphokinetic analysis: a randomized, controlled trial of the EmbryoScope. *Fertil Steril*. 2014 Nov;102(5):1287-1294. e5.
157. Rubio C, Simon C, Mercader A, Garcia-Velasco J, Remohi J, Pellicer A. Clinical experience employing co-culture of human embryos with autologous human endometrial epithelial cells. *Hum Reprod*. 2000 Dec;15 Suppl 6:31-8.
158. Russell RB, Petrini JR, Damus K, Mattison DR, Schwarz RH. The Changing Epidemiology of Multiple Births in the United States. *Obstet Gynecol*. 2003 Jan;101(1):129-35.
159. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS. Low and very low birth weight in infants conceived with use of assisted reproductive technology. *N Engl J Med*. 2002 Mar; 346(10):731-7.
160. Schiff JD, Ramirez ML, Bar-Chama N. Medical and surgical management of male infertility. *Endocrinol Metab Clin North Am*. 2007 Jun;36(2):313-31.
161. Schrage SB, Paladine HL, Cadwallader. In: *Rakel: Textbook of Family Medicine*, 8th ed. CH 25. Gynecology. Copyright © 2011 Saunders.
162. Schuster TG, Ohl DA. Diagnosis and treatment of ejaculatory dysfunction. *Urol Clin N Am*. 2002 Nov;29(4):939-48.
163. Seif MMW, Edi-Osagie ECO, Farquhar C, Hooper L, Blake D, McGinlay P. Assisted hatching on assisted conception (IVF & ICSI). *The Cochrane Database of Systematic Reviews* 2006. In: *The Cochrane Library*, 2008, Issue 2, ©2008 The Cochrane Collaboration.
164. Seifer DB, Simsek B, Wantman E, Kotlyar AM. Status of racial disparities between black and white women undergoing assisted reproductive technology in the US. *Reprod Biol Endocrinol*. 2020 Nov 19;18(1):113.
165. Sermon K, Van Steirteghem A, Liebaers I. Preimplantation genetic diagnosis. *Lancet*. 2004 May;363(9421):1633-41.
166. Society of Obstetricians and Gynaecologists of Canada (SOGC), Okun N, Sierra S. Pregnancy outcomes after assisted human reproduction. *Obstet Gynaecol Can*. 2014 Jan;36(1):64-83.
167. Song WY, Sun YP, Jin HX, Su YC, Chian RC. Clinical outcome of emergency egg vitrification for women when sperm extraction from the testicular tissue of the male partner is not successful. *Syst Biol Reprod* 2011;57:210-3.
168. Sonksen J, Ohl DA. Penile vibratory stimulation and electroejaculation in the treatment of ejaculatory dysfunction. *Int J Androl*. 2002 Dec;25(6):324-32.
169. Steiner AZ. Clinical implications of ovarian reserve testing. *Obstet Gynecol Surv*. 2009;64(2):120-128.
170. Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S, Baird DD. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. *Obstet Gynecol*. 2011 Apr;117(4):798-804.

171. Stern JE, Cedars MI, Jain T, Klein NA, Beaird CM, Grainger DA, Gibbons WE; Society for Assisted Reproductive Technology Writing Group. Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States. *Fertil Steril*. 2007 Aug;88(2):275-82. Epub 2007 Apr 18.
172. Sunderam S, Kissin DM, Crawford S, Anderson JE, Folger SG, Jamieson DJ, Barfield WD; Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC. Assisted reproductive technology surveillance -- United States, 2010. *MMWR Surveill Summ*. 2013 Dec 6;62(9):1-24.
173. Sutton MY, Anachebe NF, Lee R, Skanes H. Racial and Ethnic Disparities in Reproductive Health Services and Outcomes, 2020. *Obstet Gynecol*. 2021 Feb 1;137(2):225-233.
174. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. *Fertil Steril*. 2008;89(3):505-522.
175. Thomas K, Thomson AJ, Wood SJ, Kingsland CR, Vince G, Lewis-Jones DI. Endometrial integrin expression in women undergoing IVF and ICSI: a comparison of the two groups and fertile controls. *Hum Reprod*. 2003 Feb;18(2):364-9.
176. Tremellen K, Kolo M. Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. *Aust N Z J Obstet Gynaecol*. 2010 Dec;50(6):568-72.
177. Turek PJ, Givens CR, Schriock ED, Meng MV, Pedersen RA, Conaghan J. Testis sperm extraction and intracytoplasmic sperm injection guided by prior fine-needle aspiration mapping in patients with nonobstructive azoospermia. *Fertil Steril*. 1999 Mar;71(3):552-7.
178. Turek PJ, Ljung BM, Cha I, Conaghan J. Diagnostic findings from testis fine needle aspiration mapping in obstructed and nonobstructed azoospermic men. *J Urol*. 2000 Jun;163(6):1709-16.
179. uBiome, Inc. SmartJane™. Accessed May 7, 2019. Available at URL address: https://ubiome.com/clinical/smartjane/?utm_source=google&utm_medium=cpc&utm_campaign=Search-Brand-SJ-Broad-GP&gclid=EAlalQobChMlycXwr-j72gIVVgeGCh2DnQO8EAAYASAAEgKFA_D_BwE
180. Valojerdi MR, Karimian L, Yazdi PE, Gilani MA, Madani T, Baghestani AR. Efficacy of a human embryo transfer medium: a prospective, randomized clinical trial study. *J Assist Reprod Genet*. 2006 May;23(5):207-12.
181. Van Peperstraten A, Proctor ML, Johnson NP, Philipson G. Techniques for surgical retrieval of sperm prior to ICSI for azoospermia. *The Cochrane Database of Systematic Reviews* 2005. In *The Cochrane Library*, 2008, Issue 2, ©2008 The Cochrane Collaboration.
182. Van Waart J, Kruger TF, Lombard CJ, Ombelet W. Predictive value of normal sperm morphology in intrauterine insemination (IUI): a structure literature review. *Human Reprod Update*. 2001 Sep-Oct;7(50):495-500.
183. Varghese AC, Sinha B, Bhattacharyya AK. Current trends in evaluation of sperm function: in vitro selection and manipulation of male gametes for assisted conception. *Indian J Exp Biol*. 2005 Nov;43(11):1023-31.
184. Virant-Klun I, Bacer-Kermavner L, Tomazevic T, Vrtacnik-Bokal E. Slow oocyte freezing and thawing in couples with no sperm or an insufficient number of sperm on the day of in vitro fertilization. *Reprod Biol Endocrinol*. 2011 Feb 2;9:19.

185. Wen SW, Walker MC, Leveille MC, Leader A. Analysis. Intracytoplasmic sperm injection: promises and challenges. *Canadian Medical Association Journal*. 2004 Oct;171(8):845-6.
186. Wiemer KE, Cohen J, Tucker MJ, Godke RA. The application of co-culture in assisted reproduction: 10 years of experience with human embryos. *Hum Reprod*. 1998 Dec;13 Suppl 4:226-38.
187. Wilczyński JR1, Radwan P, Tchórzewski H, Banasik M. Immunotherapy of patients with recurrent spontaneous miscarriage and idiopathic infertility: does the immunization-dependent Th2 cytokine overbalance really matter? *Arch Immunol Ther Exp (Warsz)*. 2012 Apr;60(2):151-60.
188. Williams R, Elam G. Infertility. In: *Rakel: Textbook of Family Medicine*, 7th ed. Ch 36. Gynecology. Copyright © 2007 Saunders.
189. Wilson EE. Assisted reproductive technologies and multiple gestations. *Clin Perinatol*. 2005 Jun;32(2):315-28, v.
190. Wongtra-Ngan S, Vutyavanich T, Brown J. Follicular flushing during oocyte retrieval in assisted reproductive techniques. *Cochrane Database Syst Rev*. 2010 Sep 8;(9):CD004634.
191. Wurn BF, Wurn LJ, King CR, Heuer MA, Roscow AS, Scharf ES, Shuster JJ. Treating female infertility and improving IVF pregnancy rates with a manual physical therapy technique. *MedGenMed*. 2004 Jun 18;6(2):51.
192. Wurn BF, Wurn LJ, King CR, Heuer MA, Roscow AS, Hornberger K, Scharf ES. Treating fallopian tube occlusion with a manual pelvic physical therapy. *Altern Ther Health Med*. 2008 Jan-Feb;14(1):18-23.
193. Xi W, Gong F, Lu G. Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients. *J Assist Reprod Genet*. 2012 May;29(5):397-402.
194. Ye H, Huang GN, Gao Y, Liu de Y. Relationship between human sperm-hyaluronan binding assay and fertilization rate in conventional in vitro fertilization. *Hum Reprod*. 2006 Jun;21(6):1545-50.
195. Yun L, Liqun W, Shuqi Y, Chunxiao W, Liming L, Wei Y. Acupuncture for infertile women without undergoing assisted reproductive techniques (ART): A systematic review and meta-analysis. *Medicine (Baltimore)*. 2019 Jul;98(29):e16463.
196. Zander-Fox DL, Tremellen K, Lane M. Single blastocyst embryo transfer maintains comparable pregnancy rates to double cleavage-stage embryo transfer but results in healthier pregnancy outcomes. *Aust N Z J Obstet Gynaecol*. 2011 Oct;51(5):406-10.
197. Zini A, Libman J. Sperm DNA damage: clinical significance in the era of assisted reproduction. *CMAJ*. 2006 Aug 29;175(5):495-500.

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.